



BRITISH COLUMBIA
CENTRE *for* EXCELLENCE
in HIV/AIDS

BC HIV Treatment Program

Monthly Report
February 2025



FOREWORD

The British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) is a provincial treatment and research program, with the mandate to improve the health of people living with HIV (“PLWH”), and those at elevated risk of acquiring HIV in British Columbia (BC), by advancing and promoting programs for treatment and prevention of HIV, and related conditions, guided by Treatment as Prevention® (TasP®) principles. Funded by the BC’s Ministry of Health, through the province’s PharmaCare Program, the BC-CfE’s Drug Treatment Programs provide medications for HIV treatment, prevention, and select related conditions, at no charge, to medically eligible BC residents living with HIV, or at elevated risk of HIV acquisition. The provision of these medications are based on guidelines developed by the BC-CfE’s Committee for Drug Evaluation and Therapy (CDET) and program consideration.

A key component of the BC-CfE’s mandate is to monitor and evaluate its HIV Treatment Program, reporting on a regular basis and providing essential information to BC’s health authorities, treating clinicians, and the community at large. This HIV Treatment Program Report provides an overview of the use of antiretroviral medications in BC for the treatment of HIV, common drug combinations, key monitoring parameters, and distribution of program participants throughout the province.

Figures and graphs in this document are best viewed in colour.

Please note that any comments or queries regarding this report should be forwarded to info@bccfe.ca.

BC Centre for Excellence in HIV/AIDS Drug Treatment Programs

St. Paul’s Hospital
687 - 1081 Burrard Street
Vancouver, BC
V6Z 1Y6

Tel: 604.806.8515
Fax: 604.806.9044

Website: www.bccfe.ca
Email: info@bccfe.ca

Funding for the BC Centre for Excellence in HIV/AIDS is provided through BC’s PharmaCare and Ministry of Health.

DISCLAIMER: All information presented in this report is generated from a secure, live database maintained by the BC-CfE. Privacy and confidentiality are matters which are taken very seriously and strict rules and procedures are applied to ensure that the information stored is secure.

Figures and tables provided in this report represent the best estimates at the time the document was generated, and may be subject to change. Please be advised that the information in this document is provided in good faith and is derived from sources understood to be accurate and up-to-date at the report’s date of publication.

© 2026 BC Centre for Excellence in HIV/AIDS



TABLE OF CONTENTS

1. List of Figures

- 1.1 Distribution of Participants on Antiretroviral Treatment in British Columbia by Health Authority
- 1.2 Distribution of Participants in HIV Treatment Program by Regimen Category
- 1.3 Distribution of Participants in HIV Treatment Program by Regimen Category
- 1.4 Distribution of Participants on Nucleos(t)ide Analogue Reverse Transcriptase Inhibitors by INGREDIENT
- 1.5 Number of Participants on Nucleos(t)ide Analogue Reverse Transcriptase Inhibitors by INGREDIENT
- 1.6 Distribution of Participants on Protease Inhibitors by INGREDIENT
- 1.7 Number of Participants on Protease Inhibitors by INGREDIENT
- 1.8 Distribution of Participants on Non-Nucleoside Analogue Reverse Transcriptase Inhibitors by INGREDIENT
- 1.9 Number of Participants on Non-Nucleoside Analogue Reverse Transcriptase Inhibitors by INGREDIENT
- 1.10 Distribution of Participants on Integrase Inhibitors by INGREDIENT
- 1.11 Number of Participants on Integrase Inhibitors by INGREDIENT
- 1.12 Distribution of Participants on Other Antiretroviral Drug Classes by INGREDIENT
- 1.13 Number of Participants on Other Antiretroviral Drug Classes by INGREDIENT
- 1.14 Distribution of Participants on Antiretroviral Treatment by Number of Antiretrovirals (graph)
- 1.15 Distribution of Participants on Antiretroviral Treatment by Number of Antiretrovirals (table)
- 1.16 Percent Distribution of Active Participants by CD4 Count
- 1.17 Distribution of Active Participants by CD4 Count
- 1.18 Initial Regimen Composition for Antiretroviral Treatment Naïve Participants Starting Treatment (graph)
- 1.19 Initial Regimen Composition for Antiretroviral Treatment Naïve Participants Starting Treatment (table)
- 1.20 Pre-entry CD4 for Antiretroviral Treatment Naïve Participants in the HIV Treatment Program (graph)
- 1.21 Pre-entry CD4 for Antiretroviral Treatment Naïve Participants in the HIV Treatment Program (table)
- 1.22 Antiretroviral Resistance by Drug Class Among Participants on Antiretroviral Treatment (graph)
- 1.23 Antiretroviral Resistance by Drug Class Among Participants on Antiretroviral Treatment (table)
- 1.24 Active Participants by number of Antiretroviral Drug Classes with Resistance (graph)
- 1.25 Active Participants by number of Antiretroviral Drug Classes with Resistance (table)

2. List of Tables

- 2.1 Active participants by Year of Program Initiation (1987 - 2025) - as of January 2025
- 2.2 HIV Viral Load (copies/mL) and CD4 (cells/ μ L) for Participants on Antiretroviral Treatment
- 2.3 BC-CfE HIV Treatment Program Enrolment

3. Distribution of HIV Treatment Program Active Participants

- 3.1 Provincial Health Authorities
- 3.2 Interior Health Authority & Kelowna
- 3.3 Fraser Health Authority & Surrey
- 3.4 Vancouver Coastal Health Authority & Vancouver
- 3.5 Vancouver Island Health Authority & Victoria
- 3.6 Northern Health Authority & Prince George

TABLE OF CONTENTS (continued)

4. Health Authority Tables

INTERIOR HEALTH

- 4.1 Distribution of Participants by Age & Sex at Birth
- 4.2 Distribution of Participants by Program Duration
- 4.3 Distribution of Antiretroviral Treatment Prescribers

FRASER HEALTH

- 4.4 Distribution of Participants by Age & Sex at Birth
- 4.5 Distribution of Participants by Program Duration
- 4.6 Distribution of Antiretroviral Treatment Prescribers

VANCOUVER COASTAL

- 4.7 Distribution of Participants by Age & Sex at Birth
- 4.8 Distribution of Participants by Program Duration
- 4.9 Distribution of Antiretroviral Treatment Prescribers

VANCOUVER ISLAND

- 4.10 Distribution of Participants by Age & Sex at Birth
- 4.11 Distribution of Participants by Program Duration
- 4.12 Distribution of Antiretroviral Treatment Prescribers

NORTHERN HEALTH

- 4.13 Distribution of Participants by Age & Sex at Birth
- 4.14 Distribution of Participants by Program Duration
- 4.15 Distribution of Antiretroviral Treatment Prescribers


INDIGENOUS PARTICIPANTS

- 4.16 Distribution of Indigenous Participants by Health Service Delivery Area and Sex at Birth



1.1 Distribution of Participants on Antiretroviral Treatment in British Columbia by Health Authority February 2025

N = 7696



| Health Authority | Male | Female | All |
|---------------------------|-------------|-------------|-------------|
| FRASER | 1606 | 501 | 2107 |
| VANCOUVER ISLAND | 891 | 176 | 1067 |
| VANCOUVER COASTAL | 3204 | 446 | 3650 |
| INTERIOR | 494 | 117 | 611 |
| NORTHERN | 171 | 79 | 250 |
| | 6366 | 1319 | 7685 |
| Unknown/not stated | | | 11 |
| Total | | | 7696 |


On antiretroviral treatment is defined as being on treatment in the current month

Unknown/not stated is defined as being on treatment in the current month, and city of residence is unknown

Male & Female refer to Sex assigned at birth



1.2 Distribution of Participants in HIV Treatment Program by Regimen Category
February 2020 - February 2025



1.3 Distribution of Participants in HIV Treatment Program by Regimen Category

| MON-YYYY | Total | INSTI | | Boosted PI | | NNRTI | | 2 drugs from 2 classes | | ≥3 drugs from ≥3 classes | | Other | |
|----------|-------|-------|------|------------|-----|-------|-----|------------------------|------|--------------------------|-----|-------|-----|
| | | n | % | n | % | n | % | n | % | n | % | n | % |
| MAR-2023 | 7548 | 4735 | 62.7 | 699 | 9.3 | 653 | 8.7 | 748 | 9.9 | 644 | 8.5 | 69 | 0.9 |
| APR-2023 | 7553 | 4736 | 62.7 | 704 | 9.3 | 653 | 8.6 | 762 | 10.1 | 634 | 8.4 | 64 | 0.8 |
| MAY-2023 | 7592 | 4752 | 62.6 | 706 | 9.3 | 644 | 8.5 | 800 | 10.5 | 627 | 8.3 | 63 | 0.8 |
| JUN-2023 | 7599 | 4788 | 63.0 | 675 | 8.9 | 625 | 8.2 | 819 | 10.8 | 627 | 8.3 | 65 | 0.9 |
| JUL-2023 | 7577 | 4758 | 62.8 | 662 | 8.7 | 626 | 8.3 | 842 | 11.1 | 628 | 8.3 | 61 | 0.8 |
| AUG-2023 | 7600 | 4773 | 62.8 | 643 | 8.5 | 621 | 8.2 | 864 | 11.4 | 632 | 8.3 | 67 | 0.9 |
| SEP-2023 | 7609 | 4793 | 63.0 | 639 | 8.4 | 616 | 8.1 | 879 | 11.6 | 617 | 8.1 | 65 | 0.9 |
| OCT-2023 | 7610 | 4808 | 63.2 | 615 | 8.1 | 611 | 8.0 | 897 | 11.8 | 618 | 8.1 | 61 | 0.8 |
| NOV-2023 | 7612 | 4799 | 63.0 | 611 | 8.0 | 599 | 7.9 | 918 | 12.1 | 624 | 8.2 | 61 | 0.8 |
| DEC-2023 | 7603 | 4808 | 63.2 | 593 | 7.8 | 596 | 7.8 | 936 | 12.3 | 614 | 8.1 | 56 | 0.7 |
| JAN-2024 | 7642 | 4856 | 63.5 | 583 | 7.6 | 585 | 7.7 | 952 | 12.5 | 609 | 8.0 | 57 | 0.7 |
| FEB-2024 | 7647 | 4861 | 63.6 | 564 | 7.4 | 586 | 7.7 | 971 | 12.7 | 609 | 8.0 | 56 | 0.7 |
| MAR-2024 | 7636 | 4846 | 63.5 | 543 | 7.1 | 580 | 7.6 | 991 | 13.0 | 618 | 8.1 | 58 | 0.8 |
| APR-2024 | 7670 | 4884 | 63.7 | 538 | 7.0 | 570 | 7.4 | 1000 | 13.0 | 621 | 8.1 | 57 | 0.7 |
| MAY-2024 | 7687 | 4902 | 63.8 | 536 | 7.0 | 566 | 7.4 | 1023 | 13.3 | 607 | 7.9 | 53 | 0.7 |
| JUN-2024 | 7687 | 4910 | 63.9 | 526 | 6.8 | 556 | 7.2 | 1033 | 13.4 | 606 | 7.9 | 56 | 0.7 |
| JUL-2024 | 7718 | 4938 | 64.0 | 520 | 6.7 | 541 | 7.0 | 1060 | 13.7 | 605 | 7.8 | 54 | 0.7 |
| AUG-2024 | 7709 | 4933 | 64.0 | 505 | 6.6 | 537 | 7.0 | 1081 | 14.0 | 602 | 7.8 | 51 | 0.7 |
| SEP-2024 | 7697 | 4911 | 63.8 | 484 | 6.3 | 530 | 6.9 | 1124 | 14.6 | 595 | 7.7 | 53 | 0.7 |
| OCT-2024 | 7725 | 4938 | 63.9 | 467 | 6.0 | 512 | 6.6 | 1167 | 15.1 | 593 | 7.7 | 48 | 0.6 |
| NOV-2024 | 7703 | 4946 | 64.2 | 464 | 6.0 | 490 | 6.4 | 1176 | 15.3 | 581 | 7.5 | 46 | 0.6 |
| DEC-2024 | 7720 | 4949 | 64.1 | 456 | 5.9 | 479 | 6.2 | 1199 | 15.5 | 588 | 7.6 | 49 | 0.6 |
| JAN-2025 | 7739 | 4959 | 64.1 | 437 | 5.6 | 478 | 6.2 | 1234 | 15.9 | 586 | 7.6 | 45 | 0.6 |
| FEB-2025 | 7696 | 4929 | 64.0 | 419 | 5.4 | 460 | 6.0 | 1264 | 16.4 | 577 | 7.5 | 47 | 0.6 |

n is number of participants on the specified regimen class in the specified month


% is ratio of **n** and total number of participants on antiretroviral treatment in the specified month

INSTI: Integrase Inhibitor, **PI:** Protease Inhibitor, **NNRTI:** Non-Nucleoside Analogue Reverse Transcriptase Inhibitor,

N(t)RTI: Nucleos(t)ide Analogue Reverse Transcriptase Inhibitor



1.4 Distribution of Participants on Nucleos(t)ide Analogue Reverse Transcriptase Inhibitors by INGREDIENT
February 2020 - February 2025




1.5 Number of Participants on Nucleos(t)ide Analogue Reverse Transcriptase Inhibitors by INGREDIENT

| MON-YYYY | Total Participants | abacavir | | emtricitabine | | lamivudine | | tenofovir <TAF> | | tenofovir <TDF> | | zidovudine | |
|----------|--------------------|----------|------|---------------|------|------------|------|-----------------|------|-----------------|------|------------|-----|
| | | n | % | n | % | n | % | n | % | n | % | n | % |
| MAR-2023 | 7413 | 2071 | 27.9 | 4476 | 60.4 | 2936 | 39.6 | 3551 | 47.9 | 1051 | 14.2 | 15 | 0.2 |
| APR-2023 | 7418 | 2067 | 27.9 | 4469 | 60.3 | 2948 | 39.7 | 3550 | 47.9 | 1030 | 13.9 | 15 | 0.2 |
| MAY-2023 | 7451 | 2043 | 27.4 | 4513 | 60.6 | 2940 | 39.5 | 3598 | 48.3 | 1040 | 14.0 | 16 | 0.2 |
| JUN-2023 | 7460 | 2008 | 26.9 | 4533 | 60.8 | 2934 | 39.3 | 3655 | 49.0 | 1002 | 13.4 | 14 | 0.2 |
| JUL-2023 | 7438 | 1966 | 26.4 | 4530 | 60.9 | 2917 | 39.2 | 3678 | 49.5 | 985 | 13.2 | 14 | 0.2 |
| AUG-2023 | 7467 | 1935 | 25.9 | 4561 | 61.1 | 2909 | 39.0 | 3717 | 49.8 | 969 | 13.0 | 14 | 0.2 |
| SEP-2023 | 7478 | 1910 | 25.5 | 4578 | 61.2 | 2902 | 38.8 | 3746 | 50.1 | 954 | 12.8 | 13 | 0.2 |
| OCT-2023 | 7474 | 1895 | 25.4 | 4573 | 61.2 | 2904 | 38.9 | 3766 | 50.4 | 935 | 12.5 | 14 | 0.2 |
| NOV-2023 | 7474 | 1866 | 25.0 | 4585 | 61.4 | 2891 | 38.7 | 3783 | 50.6 | 918 | 12.3 | 15 | 0.2 |
| DEC-2023 | 7464 | 1831 | 24.5 | 4595 | 61.6 | 2874 | 38.5 | 3820 | 51.2 | 895 | 12.0 | 13 | 0.2 |
| JAN-2024 | 7502 | 1831 | 24.4 | 4633 | 61.8 | 2881 | 38.4 | 3866 | 51.5 | 890 | 11.9 | 13 | 0.2 |
| FEB-2024 | 7504 | 1795 | 23.9 | 4641 | 61.9 | 2868 | 38.2 | 3896 | 51.9 | 864 | 11.5 | 13 | 0.2 |
| MAR-2024 | 7493 | 1759 | 23.5 | 4656 | 62.1 | 2845 | 38.0 | 3927 | 52.4 | 844 | 11.3 | 13 | 0.2 |
| APR-2024 | 7525 | 1742 | 23.2 | 4690 | 62.3 | 2844 | 37.8 | 3968 | 52.7 | 843 | 11.2 | 13 | 0.2 |
| MAY-2024 | 7544 | 1706 | 22.6 | 4734 | 62.8 | 2822 | 37.4 | 4018 | 53.3 | 832 | 11.0 | 12 | 0.2 |
| JUN-2024 | 7544 | 1691 | 22.4 | 4738 | 62.8 | 2817 | 37.3 | 4047 | 53.7 | 801 | 10.6 | 13 | 0.2 |
| JUL-2024 | 7570 | 1667 | 22.0 | 4763 | 62.9 | 2812 | 37.2 | 4077 | 53.9 | 800 | 10.6 | 13 | 0.2 |
| AUG-2024 | 7563 | 1633 | 21.6 | 4771 | 63.1 | 2796 | 37.0 | 4097 | 54.2 | 782 | 10.3 | 13 | 0.2 |
| SEP-2024 | 7551 | 1600 | 21.2 | 4769 | 63.2 | 2797 | 37.0 | 4113 | 54.5 | 768 | 10.2 | 13 | 0.2 |
| OCT-2024 | 7577 | 1556 | 20.5 | 4810 | 63.5 | 2789 | 36.8 | 4170 | 55.0 | 754 | 10.0 | 13 | 0.2 |
| NOV-2024 | 7555 | 1499 | 19.8 | 4821 | 63.8 | 2744 | 36.3 | 4193 | 55.5 | 739 | 9.8 | 11 | 0.2 |
| DEC-2024 | 7572 | 1481 | 19.6 | 4835 | 63.9 | 2756 | 36.4 | 4223 | 55.8 | 734 | 9.7 | 11 | 0.2 |
| JAN-2025 | 7591 | 1431 | 18.9 | 4873 | 64.2 | 2740 | 36.1 | 4273 | 56.3 | 721 | 9.5 | 10 | 0.1 |
| FEB-2025 | 7547 | 1370 | 18.2 | 4860 | 64.4 | 2698 | 35.8 | 4280 | 56.7 | 701 | 9.3 | 8 | 0.1 |

n is defined as number of participants on antiretroviral treatment which contains the INGREDIENT;
% is calculated as ratio of "n" and number of participants whose treatment is of the given antiretroviral drug class



1.6 Distribution of Participants on Protease Inhibitors by INGREDIENT
February 2020 - February 2025




1.7 Number of Participants on Protease Inhibitors by INGREDIENT

| MON-YYYY | Total Participants | atazanavir | | darunavir | | lopinavir | | ritonavir | | tipranavir | |
|----------|--------------------|------------|------|-----------|------|-----------|-----|-----------|-----|------------|-----|
| | | n | % | n | % | n | % | n | % | n | % |
| MAR-2023 | 1308 | 317 | 24.2 | 952 | 72.8 | 42 | 3.2 | 1 | 0.1 | 1 | 0.1 |
| APR-2023 | 1301 | 305 | 23.4 | 957 | 73.6 | 41 | 3.2 | 1 | 0.1 | 1 | 0.1 |
| MAY-2023 | 1291 | 303 | 23.5 | 951 | 73.7 | 39 | 3.0 | 1 | 0.1 | 1 | 0.1 |
| JUN-2023 | 1267 | 294 | 23.2 | 936 | 73.9 | 39 | 3.1 | 1 | 0.1 | 1 | 0.1 |
| JUL-2023 | 1247 | 283 | 22.7 | 927 | 74.3 | 38 | 3.1 | 1 | 0.1 | 1 | 0.1 |
| AUG-2023 | 1225 | 276 | 22.5 | 914 | 74.6 | 36 | 2.9 | 0 | 0.0 | 0 | 0.0 |
| SEP-2023 | 1214 | 271 | 22.3 | 909 | 74.9 | 35 | 2.9 | 0 | 0.0 | 0 | 0.0 |
| OCT-2023 | 1198 | 273 | 22.8 | 893 | 74.5 | 35 | 2.9 | 0 | 0.0 | 0 | 0.0 |
| NOV-2023 | 1184 | 260 | 22.0 | 890 | 75.2 | 35 | 3.0 | 0 | 0.0 | 0 | 0.0 |
| DEC-2023 | 1156 | 248 | 21.5 | 876 | 75.8 | 33 | 2.9 | 0 | 0.0 | 0 | 0.0 |
| JAN-2024 | 1138 | 241 | 21.2 | 866 | 76.1 | 33 | 2.9 | 0 | 0.0 | 0 | 0.0 |
| FEB-2024 | 1111 | 229 | 20.6 | 852 | 76.7 | 31 | 2.8 | 0 | 0.0 | 0 | 0.0 |
| MAR-2024 | 1094 | 225 | 20.6 | 840 | 76.8 | 30 | 2.7 | 0 | 0.0 | 0 | 0.0 |
| APR-2024 | 1088 | 224 | 20.6 | 835 | 76.8 | 31 | 2.9 | 0 | 0.0 | 0 | 0.0 |
| MAY-2024 | 1081 | 221 | 20.4 | 828 | 76.6 | 33 | 3.1 | 0 | 0.0 | 0 | 0.0 |
| JUN-2024 | 1059 | 214 | 20.2 | 813 | 76.8 | 33 | 3.1 | 0 | 0.0 | 0 | 0.0 |
| JUL-2024 | 1052 | 216 | 20.5 | 805 | 76.5 | 33 | 3.1 | 0 | 0.0 | 0 | 0.0 |
| AUG-2024 | 1021 | 208 | 20.4 | 784 | 76.8 | 31 | 3.0 | 0 | 0.0 | 0 | 0.0 |
| SEP-2024 | 1001 | 203 | 20.3 | 772 | 77.1 | 27 | 2.7 | 0 | 0.0 | 0 | 0.0 |
| OCT-2024 | 977 | 197 | 20.2 | 754 | 77.2 | 27 | 2.8 | 0 | 0.0 | 0 | 0.0 |
| NOV-2024 | 957 | 190 | 19.9 | 742 | 77.5 | 28 | 2.9 | 0 | 0.0 | 0 | 0.0 |
| DEC-2024 | 947 | 184 | 19.4 | 738 | 77.9 | 26 | 2.8 | 0 | 0.0 | 0 | 0.0 |
| JAN-2025 | 922 | 177 | 19.2 | 726 | 78.7 | 23 | 2.5 | 0 | 0.0 | 0 | 0.0 |
| FEB-2025 | 891 | 168 | 18.9 | 700 | 78.6 | 24 | 2.7 | 0 | 0.0 | 0 | 0.0 |

n is defined as number of participants on antiretroviral treatment which contains the INGREDIENT;
 % is calculated as ratio of "n" and number of participants whose treatment is of the given antiretroviral drug class
 Ritonavir - greater than 400 mg total daily dose

1.8 Distribution of Participants on Non-Nucleoside Analogue Reverse Transcriptase Inhibitors by INGREDIENT
February 2020 - February 2025




1.9 Number of Participants on Non-Nucleoside Analogue Reverse Transcriptase Inhibitors by INGREDIENT

| MON-YYYY | Total Participants | doravirine n % | efavirenz n % | etravirine n % | nevirapine n % | rilpivirine n % |
|----------|--------------------|-------------------|------------------|-------------------|-------------------|--------------------|
| MAR-2023 | 981 | 209 21.3 | 242 24.7 | 101 10.3 | 246 25.1 | 186 19.0 |
| APR-2023 | 970 | 215 22.2 | 232 23.9 | 96 9.9 | 245 25.3 | 187 19.3 |
| MAY-2023 | 977 | 223 22.8 | 232 23.8 | 98 10.0 | 239 24.5 | 187 19.1 |
| JUN-2023 | 954 | 224 23.5 | 228 23.9 | 96 10.1 | 230 24.1 | 180 18.9 |
| JUL-2023 | 953 | 235 24.7 | 222 23.3 | 94 9.9 | 225 23.6 | 178 18.7 |
| AUG-2023 | 951 | 238 25.0 | 222 23.3 | 91 9.6 | 223 23.5 | 182 19.1 |
| SEP-2023 | 938 | 236 25.2 | 218 23.2 | 88 9.4 | 220 23.5 | 177 18.9 |
| OCT-2023 | 932 | 238 25.5 | 216 23.2 | 89 9.6 | 220 23.6 | 173 18.6 |
| NOV-2023 | 928 | 242 26.1 | 209 22.5 | 88 9.5 | 219 23.6 | 173 18.6 |
| DEC-2023 | 929 | 250 26.9 | 205 22.1 | 87 9.4 | 213 22.9 | 176 19.0 |
| JAN-2024 | 921 | 250 27.1 | 200 21.7 | 83 9.0 | 208 22.6 | 181 19.7 |
| FEB-2024 | 919 | 257 28.0 | 192 20.9 | 82 8.9 | 207 22.5 | 182 19.8 |
| MAR-2024 | 914 | 260 28.5 | 190 20.8 | 80 8.8 | 205 22.4 | 181 19.8 |
| APR-2024 | 915 | 261 28.5 | 190 20.8 | 82 9.0 | 203 22.2 | 180 19.7 |
| MAY-2024 | 906 | 262 28.9 | 186 20.5 | 80 8.8 | 205 22.6 | 175 19.3 |
| JUN-2024 | 893 | 262 29.3 | 182 20.4 | 79 8.9 | 198 22.2 | 172 19.3 |
| JUL-2024 | 890 | 270 30.3 | 176 19.8 | 78 8.8 | 194 21.8 | 172 19.3 |
| AUG-2024 | 879 | 272 30.9 | 174 19.8 | 78 8.9 | 187 21.3 | 171 19.5 |
| SEP-2024 | 886 | 275 31.0 | 172 19.4 | 76 8.6 | 185 20.9 | 179 20.2 |
| OCT-2024 | 871 | 283 32.5 | 168 19.3 | 72 8.3 | 177 20.3 | 175 20.1 |
| NOV-2024 | 850 | 287 33.8 | 162 19.1 | 70 8.2 | 159 18.7 | 173 20.4 |
| DEC-2024 | 844 | 303 35.9 | 156 18.5 | 71 8.4 | 149 17.7 | 167 19.8 |
| JAN-2025 | 844 | 309 36.6 | 157 18.6 | 67 7.9 | 143 16.9 | 172 20.4 |
| FEB-2025 | 834 | 306 36.7 | 156 18.7 | 64 7.7 | 136 16.3 | 173 20.7 |

n is defined as number of participants on antiretroviral treatment which contains the INGREDIENT;
% is calculated as ratio of "n" and number of participants whose treatment is of the given antiretroviral drug class

1.10 Distribution of Participants on Integrase Inhibitors by INGREDIENT
February 2020 - February 2025






1.11 Number of Participants on Integrase Inhibitors by INGREDIENT

| MON-YYYY | Total Participants | bictegravir n % | cabotegravir n % | dolutegravir n % | elvitegravir n % | raltegravir n % |
|----------|--------------------|--------------------|---------------------|---------------------|---------------------|--------------------|
| MAR-2023 | 6093 | 3084 50.6 | 0 0.0 | 2482 40.7 | 259 4.3 | 291 4.8 |
| APR-2023 | 6103 | 3084 50.5 | 0 0.0 | 2498 40.9 | 258 4.2 | 274 4.5 |
| MAY-2023 | 6151 | 3138 51.0 | 3 0.1 | 2504 40.7 | 250 4.1 | 278 4.5 |
| JUN-2023 | 6204 | 3197 51.5 | 5 0.1 | 2509 40.4 | 248 4.0 | 267 4.3 |
| JUL-2023 | 6201 | 3218 51.9 | 5 0.1 | 2499 40.3 | 247 4.0 | 256 4.1 |
| AUG-2023 | 6240 | 3258 52.2 | 7 0.1 | 2495 40.0 | 245 3.9 | 253 4.1 |
| SEP-2023 | 6263 | 3289 52.5 | 8 0.1 | 2500 39.9 | 238 3.8 | 249 4.0 |
| OCT-2023 | 6294 | 3298 52.4 | 7 0.1 | 2523 40.1 | 241 3.8 | 248 3.9 |
| NOV-2023 | 6311 | 3327 52.7 | 9 0.1 | 2518 39.9 | 233 3.7 | 244 3.9 |
| DEC-2023 | 6330 | 3365 53.2 | 13 0.2 | 2506 39.6 | 226 3.6 | 237 3.7 |
| JAN-2024 | 6389 | 3418 53.5 | 16 0.3 | 2520 39.4 | 224 3.5 | 234 3.7 |
| FEB-2024 | 6417 | 3453 53.8 | 15 0.2 | 2516 39.2 | 219 3.4 | 231 3.6 |
| MAR-2024 | 6435 | 3498 54.4 | 17 0.3 | 2500 38.9 | 220 3.4 | 225 3.5 |
| APR-2024 | 6483 | 3545 54.7 | 17 0.3 | 2497 38.5 | 216 3.3 | 225 3.5 |
| MAY-2024 | 6511 | 3586 55.1 | 19 0.3 | 2488 38.2 | 213 3.3 | 222 3.4 |
| JUN-2024 | 6528 | 3614 55.4 | 21 0.3 | 2488 38.1 | 207 3.2 | 218 3.3 |
| JUL-2024 | 6584 | 3650 55.4 | 25 0.4 | 2500 38.0 | 212 3.2 | 213 3.2 |
| AUG-2024 | 6593 | 3683 55.9 | 26 0.4 | 2487 37.7 | 204 3.1 | 207 3.1 |
| SEP-2024 | 6610 | 3700 56.0 | 32 0.5 | 2495 37.8 | 200 3.0 | 205 3.1 |
| OCT-2024 | 6680 | 3757 56.2 | 34 0.5 | 2508 37.5 | 198 3.0 | 199 3.0 |
| NOV-2024 | 6681 | 3791 56.7 | 33 0.5 | 2487 37.2 | 191 2.9 | 193 2.9 |
| DEC-2024 | 6720 | 3819 56.8 | 33 0.5 | 2521 37.5 | 185 2.8 | 187 2.8 |
| JAN-2025 | 6762 | 3866 57.2 | 36 0.5 | 2525 37.3 | 185 2.7 | 179 2.7 |
| FEB-2025 | 6754 | 3883 57.5 | 41 0.6 | 2495 36.9 | 183 2.7 | 176 2.6 |

n is defined as number of participants on antiretroviral treatment which contains the INGREDIENT;
% is calculated as ratio of "n" and number of participants whose treatment is of the given antiretroviral drug class



1.12 Distribution of Participants on Other Antiretroviral Drug Classes by INGREDIENT
February 2020 - February 2025






1.13 Number of Participants on Other Antiretroviral Drug Classes by INGREDIENT

| MON-YYYY | Total Participants | fostemsavir | | maraviroc | | lenacapavir | |
|----------|--------------------|-------------|------|-----------|------|-------------|------|
| | | n | % | n | % | n | % |
| MAR-2023 | 22 | 2 | 9.1 | 20 | 90.9 | 0 | 0.0 |
| APR-2023 | 20 | 2 | 10.0 | 18 | 90.0 | 0 | 0.0 |
| MAY-2023 | 20 | 2 | 10.0 | 18 | 90.0 | 0 | 0.0 |
| JUN-2023 | 20 | 2 | 10.0 | 18 | 90.0 | 0 | 0.0 |
| JUL-2023 | 20 | 2 | 10.0 | 18 | 90.0 | 0 | 0.0 |
| AUG-2023 | 20 | 2 | 10.0 | 18 | 90.0 | 0 | 0.0 |
| SEP-2023 | 20 | 2 | 10.0 | 18 | 90.0 | 0 | 0.0 |
| OCT-2023 | 20 | 2 | 10.0 | 18 | 90.0 | 1 | 5.0 |
| NOV-2023 | 19 | 1 | 5.3 | 17 | 89.5 | 1 | 5.3 |
| DEC-2023 | 19 | 2 | 10.5 | 16 | 84.2 | 1 | 5.3 |
| JAN-2024 | 21 | 2 | 9.5 | 18 | 85.7 | 1 | 4.8 |
| FEB-2024 | 21 | 2 | 9.5 | 18 | 85.7 | 1 | 4.8 |
| MAR-2024 | 21 | 3 | 14.3 | 17 | 81.0 | 2 | 9.5 |
| APR-2024 | 22 | 2 | 9.1 | 18 | 81.8 | 2 | 9.1 |
| MAY-2024 | 19 | 2 | 10.5 | 15 | 79.0 | 2 | 10.5 |
| JUN-2024 | 21 | 2 | 9.5 | 17 | 81.0 | 2 | 9.5 |
| JUL-2024 | 21 | 2 | 9.5 | 17 | 81.0 | 2 | 9.5 |
| AUG-2024 | 21 | 2 | 9.5 | 17 | 81.0 | 2 | 9.5 |
| SEP-2024 | 20 | 2 | 10.0 | 16 | 80.0 | 2 | 10.0 |
| OCT-2024 | 20 | 2 | 10.0 | 15 | 75.0 | 3 | 15.0 |
| NOV-2024 | 20 | 2 | 10.0 | 16 | 80.0 | 2 | 10.0 |
| DEC-2024 | 20 | 2 | 10.0 | 16 | 80.0 | 2 | 10.0 |
| JAN-2025 | 20 | 2 | 10.0 | 16 | 80.0 | 2 | 10.0 |
| FEB-2025 | 19 | 2 | 10.5 | 15 | 79.0 | 2 | 10.5 |

n is defined as number of participants on antiretroviral treatment which contains the INGREDIENT;
 % is calculated as ratio of "n" and number of participants whose treatment is of the given antiretroviral drug class
 Both lenacapavir and fostemsavir are currently not on BC-CfE Formulary



1.14 Distribution of Participants on Antiretroviral Treatment by Number of Antiretrovirals
February 2020 - February 2025




1.15 Distribution of Participants on Antiretroviral Treatment by Number of Antiretrovirals

| MON-YYYY | Total Participants | 1 drug | | 2 drugs | | 3 drugs | | 4 drugs | | 5 or more drugs | |
|----------|--------------------|--------|-----|---------|------|---------|------|---------|-----|-----------------|-----|
| | | n | % | n | % | n | % | n | % | n | % |
| MAR-2023 | 7548 | 2 | 0.0 | 748 | 9.9 | 6312 | 83.6 | 445 | 5.9 | 41 | 0.5 |
| APR-2023 | 7553 | 2 | 0.0 | 763 | 10.1 | 6307 | 83.5 | 440 | 5.8 | 41 | 0.5 |
| MAY-2023 | 7592 | 2 | 0.0 | 800 | 10.5 | 6314 | 83.2 | 435 | 5.7 | 41 | 0.5 |
| JUN-2023 | 7599 | 2 | 0.0 | 819 | 10.8 | 6299 | 82.9 | 438 | 5.8 | 41 | 0.5 |
| JUL-2023 | 7577 | 2 | 0.0 | 842 | 11.1 | 6253 | 82.5 | 440 | 5.8 | 40 | 0.5 |
| AUG-2023 | 7600 | 2 | 0.0 | 864 | 11.4 | 6240 | 82.1 | 448 | 5.9 | 46 | 0.6 |
| SEP-2023 | 7609 | 2 | 0.0 | 879 | 11.6 | 6250 | 82.1 | 432 | 5.7 | 46 | 0.6 |
| OCT-2023 | 7610 | 2 | 0.0 | 897 | 11.8 | 6237 | 82.0 | 433 | 5.7 | 41 | 0.5 |
| NOV-2023 | 7612 | 2 | 0.0 | 918 | 12.1 | 6210 | 81.6 | 441 | 5.8 | 41 | 0.5 |
| DEC-2023 | 7603 | 2 | 0.0 | 936 | 12.3 | 6191 | 81.4 | 434 | 5.7 | 40 | 0.5 |
| JAN-2024 | 7642 | 2 | 0.0 | 952 | 12.5 | 6214 | 81.3 | 432 | 5.7 | 42 | 0.6 |
| FEB-2024 | 7647 | 3 | 0.0 | 971 | 12.7 | 6198 | 81.1 | 436 | 5.7 | 39 | 0.5 |
| MAR-2024 | 7636 | 2 | 0.0 | 991 | 13.0 | 6159 | 80.7 | 440 | 5.8 | 44 | 0.6 |
| APR-2024 | 7670 | 2 | 0.0 | 1001 | 13.1 | 6184 | 80.6 | 437 | 5.7 | 46 | 0.6 |
| MAY-2024 | 7687 | 2 | 0.0 | 1024 | 13.3 | 6188 | 80.5 | 434 | 5.7 | 39 | 0.5 |
| JUN-2024 | 7687 | 1 | 0.0 | 1034 | 13.5 | 6181 | 80.4 | 429 | 5.6 | 42 | 0.6 |
| JUL-2024 | 7718 | 2 | 0.0 | 1061 | 13.8 | 6184 | 80.1 | 434 | 5.6 | 37 | 0.5 |
| AUG-2024 | 7709 | 2 | 0.0 | 1082 | 14.0 | 6155 | 79.8 | 431 | 5.6 | 39 | 0.5 |
| SEP-2024 | 7697 | 2 | 0.0 | 1125 | 14.6 | 6101 | 79.3 | 426 | 5.5 | 43 | 0.6 |
| OCT-2024 | 7725 | 1 | 0.0 | 1169 | 15.1 | 6087 | 78.8 | 427 | 5.5 | 41 | 0.5 |
| NOV-2024 | 7703 | 1 | 0.0 | 1177 | 15.3 | 6069 | 78.8 | 417 | 5.4 | 39 | 0.5 |
| DEC-2024 | 7720 | 2 | 0.0 | 1200 | 15.5 | 6054 | 78.4 | 424 | 5.5 | 40 | 0.5 |
| JAN-2025 | 7739 | 2 | 0.0 | 1235 | 16.0 | 6047 | 78.1 | 416 | 5.4 | 39 | 0.5 |
| FEB-2025 | 7696 | 2 | 0.0 | 1265 | 16.4 | 5977 | 77.7 | 414 | 5.4 | 38 | 0.5 |

n is the number of individual drugs in antiretroviral treatment regimen (excluding low dose ritonavir and cobicistat used for pharmacokinetic boosting)



1.16 Percent Distribution of Active Participants by CD4 Count
February 2020 - February 2025





1.17 Distribution of Active Participants by CD4 Count

| Month | # of Pts with CD4: Unreported | # of Pts with CD4: < 200 | # of Pts with CD4: 200 - 349 | # of Pts with CD4: 350 - 500 | # of Pts with CD4: > 500 |
|----------|-------------------------------|--------------------------|------------------------------|------------------------------|--------------------------|
| MAR-2023 | 1110 | 247 | 538 | 994 | 3835 |
| APR-2023 | 1140 | 244 | 528 | 989 | 3836 |
| MAY-2023 | 1180 | 251 | 549 | 961 | 3837 |
| JUN-2023 | 1199 | 247 | 554 | 963 | 3827 |
| JUL-2023 | 1233 | 239 | 578 | 927 | 3805 |
| AUG-2023 | 1277 | 254 | 560 | 943 | 3767 |
| SEP-2023 | 1330 | 243 | 547 | 951 | 3744 |
| OCT-2023 | 1380 | 242 | 543 | 943 | 3727 |
| NOV-2023 | 1416 | 237 | 542 | 937 | 3689 |
| DEC-2023 | 1459 | 237 | 530 | 917 | 3703 |
| JAN-2024 | 1496 | 238 | 529 | 916 | 3679 |
| FEB-2024 | 1535 | 242 | 503 | 911 | 3673 |
| MAR-2024 | 1567 | 255 | 498 | 924 | 3649 |
| APR-2024 | 1612 | 253 | 486 | 944 | 3627 |
| MAY-2024 | 1647 | 248 | 486 | 923 | 3661 |
| JUN-2024 | 1686 | 247 | 493 | 886 | 3679 |
| JUL-2024 | 1748 | 248 | 493 | 912 | 3681 |
| AUG-2024 | 1793 | 251 | 491 | 910 | 3659 |
| SEP-2024 | 1812 | 241 | 489 | 935 | 3638 |
| OCT-2024 | 1847 | 243 | 499 | 948 | 3624 |
| NOV-2024 | 1882 | 234 | 505 | 917 | 3652 |
| DEC-2024 | 1911 | 232 | 508 | 928 | 3658 |
| JAN-2025 | 1940 | 233 | 509 | 939 | 3650 |
| FEB-2025 | 1959 | 223 | 511 | 930 | 3640 |


CD4 value (cells/μL) as per the most recent test within the past 12 months

CD4 Unreported: CD4 not tested or reported within the past 12 months

Active Participants are participants with antiretroviral treatment in the month based on dispensing record



1.18 Initial Regimen Composition for Antiretroviral Treatment Naïve Participants Starting Treatment
February 2020 - February 2025




1.19 Initial Regimen Composition for Antiretroviral Treatment Naïve Participants Starting Treatment

| MON-YYYY | Total | INSTI 2 N(t)RTIs | | Boosted PI 2 N(t)RTIs | | NNRTI 2 N(t)RTIs | | 2 drugs from 2 classes | | ≥3 drugs from ≥3 classes | | Other | |
|----------|-------|---------------------|-------|--------------------------|-----|---------------------|------|---------------------------|------|-----------------------------|------|-------|-----|
| | | n | % | n | % | n | % | n | % | n | % | n | % |
| MAR-2023 | 17 | 16 | 94.1 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 5.9 | 0 | 0.0 |
| APR-2023 | 10 | 9 | 90.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 10.0 | 0 | 0.0 |
| MAY-2023 | 14 | 13 | 92.9 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 7.1 | 0 | 0.0 |
| JUN-2023 | 17 | 17 | 100.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| JUL-2023 | 11 | 8 | 72.7 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 3 | 27.3 | 0 | 0.0 |
| AUG-2023 | 13 | 12 | 92.3 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 7.7 | 0 | 0.0 |
| SEP-2023 | 5 | 5 | 100.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| OCT-2023 | 10 | 9 | 90.0 | 0 | 0.0 | 0 | 0.0 | 1 | 10.0 | 0 | 0.0 | 0 | 0.0 |
| NOV-2023 | 9 | 7 | 77.8 | 0 | 0.0 | 0 | 0.0 | 1 | 11.1 | 1 | 11.1 | 0 | 0.0 |
| DEC-2023 | 13 | 12 | 92.3 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 7.7 | 0 | 0.0 |
| JAN-2024 | 11 | 9 | 81.8 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 2 | 18.2 | 0 | 0.0 |
| FEB-2024 | 11 | 11 | 100.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| MAR-2024 | 13 | 12 | 92.3 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 7.7 | 0 | 0.0 |
| APR-2024 | 20 | 18 | 90.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 2 | 10.0 | 0 | 0.0 |
| MAY-2024 | 16 | 16 | 100.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| JUN-2024 | 23 | 22 | 95.7 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 4.3 | 0 | 0.0 |
| JUL-2024 | 10 | 10 | 100.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| AUG-2024 | 15 | 15 | 100.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| SEP-2024 | 7 | 7 | 100.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| OCT-2024 | 15 | 15 | 100.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| NOV-2024 | 9 | 8 | 88.9 | 0 | 0.0 | 1 | 11.1 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| DEC-2024 | 10 | 10 | 100.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| JAN-2025 | 14 | 14 | 100.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| FEB-2025 | 9 | 9 | 100.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |

INSTI: Integrase Inhibitor, **PI:** Protease Inhibitor, **NNRTI:** Non-Nucleoside Analogue Reverse Transcriptase Inhibitor, **N(t)RTI:** Nucleos(t)ide Analogue Reverse Transcriptase Inhibitor
n is number of participants on the specified regimen category in the specified month
% is ratio of n and total number of participants initiating antiretroviral treatment in the specified month



1.20 Pre-entry CD4 for Antiretroviral Treatment Naïve Participants in the HIV Treatment Program
February 2020 - February 2025




1.21 Pre-entry CD4 for Antiretroviral Treatment Naive Participants in the HIV Treatment Program

| MON-YYYY | # of First Starts | # of Pts with CD4: Unreported | | # of Pts with CD4: < 200 | | # of Pts with CD4: 200 - 349 | | # of Pts with CD4: 350 - 500 | | # of Pts with CD4: > 500 | |
|----------|-------------------|-------------------------------|------|--------------------------|------|------------------------------|------|------------------------------|------|--------------------------|------|
| | | n | % | n | % | n | % | n | % | n | % |
| MAR-2023 | 17 | 3 | 17.7 | 0 | 0.0 | 4 | 23.5 | 3 | 17.7 | 7 | 41.2 |
| APR-2023 | 10 | 1 | 10.0 | 3 | 30.0 | 1 | 10.0 | 1 | 10.0 | 4 | 40.0 |
| MAY-2023 | 14 | 3 | 21.4 | 3 | 21.4 | 2 | 14.3 | 5 | 35.7 | 1 | 7.1 |
| JUN-2023 | 17 | 0 | 0.0 | 6 | 35.3 | 3 | 17.7 | 2 | 11.8 | 6 | 35.3 |
| JUL-2023 | 11 | 0 | 0.0 | 3 | 27.3 | 3 | 27.3 | 2 | 18.2 | 3 | 27.3 |
| AUG-2023 | 13 | 2 | 15.4 | 3 | 23.1 | 4 | 30.8 | 2 | 15.4 | 2 | 15.4 |
| SEP-2023 | 5 | 0 | 0.0 | 2 | 40.0 | 0 | 0.0 | 0 | 0.0 | 3 | 60.0 |
| OCT-2023 | 10 | 1 | 10.0 | 1 | 10.0 | 3 | 30.0 | 2 | 20.0 | 3 | 30.0 |
| NOV-2023 | 9 | 1 | 11.1 | 2 | 22.2 | 0 | 0.0 | 2 | 22.2 | 4 | 44.4 |
| DEC-2023 | 13 | 1 | 7.7 | 1 | 7.7 | 3 | 23.1 | 0 | 0.0 | 8 | 61.5 |
| JAN-2024 | 11 | 1 | 9.1 | 4 | 36.4 | 2 | 18.2 | 1 | 9.1 | 3 | 27.3 |
| FEB-2024 | 11 | 1 | 9.1 | 3 | 27.3 | 4 | 36.4 | 2 | 18.2 | 1 | 9.1 |
| MAR-2024 | 13 | 2 | 15.4 | 5 | 38.5 | 1 | 7.7 | 1 | 7.7 | 4 | 30.8 |
| APR-2024 | 20 | 0 | 0.0 | 4 | 20.0 | 6 | 30.0 | 1 | 5.0 | 9 | 45.0 |
| MAY-2024 | 16 | 1 | 6.3 | 5 | 31.3 | 3 | 18.8 | 1 | 6.3 | 6 | 37.5 |
| JUN-2024 | 23 | 0 | 0.0 | 2 | 8.7 | 10 | 43.5 | 4 | 17.4 | 7 | 30.4 |
| JUL-2024 | 10 | 1 | 10.0 | 1 | 10.0 | 3 | 30.0 | 3 | 30.0 | 2 | 20.0 |
| AUG-2024 | 15 | 0 | 0.0 | 5 | 33.3 | 4 | 26.7 | 3 | 20.0 | 3 | 20.0 |
| SEP-2024 | 7 | 0 | 0.0 | 1 | 14.3 | 4 | 57.1 | 1 | 14.3 | 1 | 14.3 |
| OCT-2024 | 15 | 0 | 0.0 | 6 | 40.0 | 3 | 20.0 | 3 | 20.0 | 3 | 20.0 |
| NOV-2024 | 9 | 0 | 0.0 | 3 | 33.3 | 3 | 33.3 | 2 | 22.2 | 1 | 11.1 |
| DEC-2024 | 10 | 0 | 0.0 | 4 | 40.0 | 2 | 20.0 | 2 | 20.0 | 2 | 20.0 |
| JAN-2025 | 14 | 0 | 0.0 | 6 | 42.9 | 2 | 14.3 | 5 | 35.7 | 1 | 7.1 |
| FEB-2025 | 9 | 0 | 0.0 | 2 | 22.2 | 1 | 11.1 | 3 | 33.3 | 3 | 33.3 |

First Starts defined as participants starting antiretroviral treatment in the specified month for the first time (antiretroviral treatment naive)

Pre-entry CD4 (cells/ μ L) is defined as most recent CD4 test before antiretroviral treatment start

1.22 Antiretroviral Resistance by Drug Class Among Participants on Antiretroviral Treatment
February 2020 - February 2025



1.23 Antiretroviral Resistance by Drug Class Among Participants on Antiretroviral Treatment

| MON-YYYY | On Antiretroviral (ARV) Treatment | Ever Tested | NNRTI | | N(t)RTI | | PI | | INSTI | |
|----------|-----------------------------------|-------------|-------|------|---------|------|-----|-----|-------|-----|
| | | | n | % | n | % | n | % | n | % |
| MAR-2023 | 7532 | 6421 | 1325 | 20.6 | 1676 | 26.1 | 564 | 8.8 | 101 | 1.6 |
| APR-2023 | 7531 | 6416 | 1332 | 20.8 | 1674 | 26.1 | 566 | 8.8 | 99 | 1.5 |
| MAY-2023 | 7574 | 6449 | 1329 | 20.6 | 1681 | 26.1 | 563 | 8.7 | 106 | 1.6 |
| JUN-2023 | 7577 | 6441 | 1312 | 20.4 | 1672 | 26.0 | 561 | 8.7 | 106 | 1.7 |
| JUL-2023 | 7555 | 6417 | 1313 | 20.5 | 1678 | 26.2 | 563 | 8.8 | 106 | 1.7 |
| AUG-2023 | 7577 | 6417 | 1313 | 20.5 | 1663 | 25.9 | 557 | 8.7 | 107 | 1.7 |
| SEP-2023 | 7579 | 6402 | 1304 | 20.4 | 1644 | 25.7 | 557 | 8.7 | 104 | 1.6 |
| OCT-2023 | 7579 | 6390 | 1307 | 20.5 | 1647 | 25.8 | 552 | 8.6 | 99 | 1.6 |
| NOV-2023 | 7578 | 6384 | 1307 | 20.5 | 1643 | 25.7 | 558 | 8.7 | 101 | 1.6 |
| DEC-2023 | 7574 | 6370 | 1306 | 20.5 | 1633 | 25.6 | 553 | 8.7 | 100 | 1.6 |
| JAN-2024 | 7613 | 6395 | 1306 | 20.4 | 1644 | 25.7 | 549 | 8.6 | 102 | 1.6 |
| FEB-2024 | 7620 | 6405 | 1301 | 20.3 | 1646 | 25.7 | 562 | 8.8 | 102 | 1.6 |
| MAR-2024 | 7616 | 6389 | 1294 | 20.3 | 1637 | 25.6 | 555 | 8.7 | 105 | 1.6 |
| APR-2024 | 7647 | 6407 | 1299 | 20.3 | 1636 | 25.5 | 563 | 8.8 | 102 | 1.6 |
| MAY-2024 | 7666 | 6415 | 1301 | 20.3 | 1636 | 25.5 | 566 | 8.8 | 103 | 1.6 |
| JUN-2024 | 7678 | 6415 | 1306 | 20.4 | 1625 | 25.3 | 560 | 8.7 | 101 | 1.6 |
| JUL-2024 | 7697 | 6421 | 1315 | 20.5 | 1635 | 25.5 | 557 | 8.7 | 107 | 1.7 |
| AUG-2024 | 7686 | 6406 | 1304 | 20.4 | 1619 | 25.3 | 547 | 8.5 | 105 | 1.6 |
| SEP-2024 | 7674 | 6387 | 1299 | 20.3 | 1621 | 25.4 | 553 | 8.7 | 102 | 1.6 |
| OCT-2024 | 7702 | 6404 | 1285 | 20.1 | 1617 | 25.3 | 555 | 8.7 | 99 | 1.6 |
| NOV-2024 | 7674 | 6370 | 1279 | 20.1 | 1613 | 25.3 | 544 | 8.5 | 97 | 1.5 |
| DEC-2024 | 7693 | 6369 | 1279 | 20.1 | 1600 | 25.1 | 541 | 8.5 | 101 | 1.6 |
| JAN-2025 | 7712 | 6370 | 1272 | 20.0 | 1587 | 24.9 | 529 | 8.3 | 105 | 1.7 |
| FEB-2025 | 7673 | 6324 | 1268 | 20.1 | 1574 | 24.9 | 530 | 8.4 | 106 | 1.7 |

On Antiretroviral (ARV) Treatment: based on dispensing data, participants with a record of ARV medication in the specified month and not deceased or moved out of program.

Ever Tested: those on ARV treatment, with at least one ARV resistance test on record in BC, up until the month of interest.

n: number of participants on ARV treatment who were ever tested for ARV resistance with drug resistance to ≥ 1 drug in the corresponding drug class in BC. Participants may have resistance to none or 1 or more drug class(es).

% is calculated as ratio of "n" and number of participants on ARV treatment who were ever tested for ARV resistance with drug resistance to ≥ 1 drug the corresponding drug class in BC.


Resistance interpretations are performed using the Stanford University HIV Drug Resistance Database Algorithm (HIVdb) version 9.8. HIVdb scores ≥ 15 are classified as "resistant".

INSTI: Integrase Inhibitor, **PI:** Protease Inhibitor, **NNRTI:** Non-Nucleoside Analogue Reverse Transcriptase Inhibitor,

N(t)RTI: Nucleos(t)ide Analogue Reverse Transcriptase Inhibitor



1.24 Active Participants by number of Antiretroviral Drug Classes with Resistance
February 2020 - February 2025





1.25 Active Participants by number of Antiretroviral Drug Classes with Resistance

| MON-YYYY | On Antiretroviral Treatment | Ever Tested | 0-Class (Wild Type) | | 1-Class | | 2-Class | | 3 or more Class | |
|----------|-----------------------------|-------------|---------------------|------|---------|------|---------|------|-----------------|-----|
| | | | n | % | n | % | n | % | n | % |
| MAR-2023 | 7532 | 6421 | 4091 | 63.7 | 1279 | 19.9 | 770 | 12.0 | 281 | 4.4 |
| APR-2023 | 7531 | 6416 | 4082 | 63.6 | 1281 | 20.0 | 773 | 12.1 | 280 | 4.4 |
| MAY-2023 | 7574 | 6449 | 4102 | 63.6 | 1296 | 20.1 | 774 | 12.0 | 277 | 4.3 |
| JUN-2023 | 7577 | 6441 | 4109 | 63.8 | 1294 | 20.1 | 761 | 11.8 | 277 | 4.3 |
| JUL-2023 | 7555 | 6417 | 4084 | 63.6 | 1289 | 20.1 | 765 | 11.9 | 279 | 4.4 |
| AUG-2023 | 7577 | 6417 | 4094 | 63.8 | 1286 | 20.0 | 761 | 11.9 | 276 | 4.3 |
| SEP-2023 | 7579 | 6402 | 4095 | 64.0 | 1280 | 20.0 | 755 | 11.8 | 272 | 4.3 |
| OCT-2023 | 7579 | 6390 | 4083 | 63.9 | 1281 | 20.1 | 758 | 11.9 | 268 | 4.2 |
| NOV-2023 | 7578 | 6384 | 4073 | 63.8 | 1287 | 20.2 | 754 | 11.8 | 270 | 4.2 |
| DEC-2023 | 7574 | 6370 | 4067 | 63.9 | 1286 | 20.2 | 749 | 11.8 | 268 | 4.2 |
| JAN-2024 | 7613 | 6395 | 4084 | 63.9 | 1292 | 20.2 | 751 | 11.7 | 268 | 4.2 |
| FEB-2024 | 7620 | 6405 | 4095 | 63.9 | 1284 | 20.1 | 755 | 11.8 | 271 | 4.2 |
| MAR-2024 | 7616 | 6389 | 4093 | 64.1 | 1276 | 20.0 | 749 | 11.7 | 271 | 4.2 |
| APR-2024 | 7647 | 6407 | 4100 | 64.0 | 1291 | 20.2 | 743 | 11.6 | 273 | 4.3 |
| MAY-2024 | 7666 | 6415 | 4104 | 64.0 | 1291 | 20.1 | 749 | 11.7 | 271 | 4.2 |
| JUN-2024 | 7678 | 6415 | 4114 | 64.1 | 1285 | 20.0 | 743 | 11.6 | 273 | 4.3 |
| JUL-2024 | 7697 | 6421 | 4107 | 64.0 | 1293 | 20.1 | 746 | 11.6 | 275 | 4.3 |
| AUG-2024 | 7686 | 6406 | 4112 | 64.2 | 1287 | 20.1 | 737 | 11.5 | 270 | 4.2 |
| SEP-2024 | 7674 | 6387 | 4095 | 64.1 | 1285 | 20.1 | 735 | 11.5 | 272 | 4.3 |
| OCT-2024 | 7702 | 6404 | 4117 | 64.3 | 1287 | 20.1 | 734 | 11.5 | 266 | 4.2 |
| NOV-2024 | 7674 | 6370 | 4095 | 64.3 | 1281 | 20.1 | 732 | 11.5 | 262 | 4.1 |
| DEC-2024 | 7693 | 6369 | 4101 | 64.4 | 1276 | 20.0 | 733 | 11.5 | 259 | 4.1 |
| JAN-2025 | 7712 | 6370 | 4112 | 64.6 | 1276 | 20.0 | 731 | 11.5 | 251 | 3.9 |
| FEB-2025 | 7673 | 6324 | 4075 | 64.4 | 1273 | 20.1 | 724 | 11.5 | 252 | 4.0 |

Number of Antiretroviral (ARV) Drug Classes with Resistance considers N(t)RTIs, NNRTIs, PIs, and INSTIs only, based on cumulative resistance tests performed in BC (until the specified month) for participants ever tested (see definition below).

Resistance interpretations are performed using the Stanford University HIV Drug Resistance Database Algorithm (HIVdb) version 9.8.

HIVdb scores ≥ 15 are classified as "resistant".

On Antiretroviral Treatment: based on dispensing data, participants with a record of ARV medication in the specified month and not deceased or moved out of program.

Ever tested: those on ARV treatment, with at least one ARV resistance test on record in BC, up until the specified month.





2.1 Active participants by Year of Program Initiation (1987 - 2025) - as of February 2025

| DTP Start Year | Duration (years) Median | First Starts | All | Male | Female | Age | | (n) | CD4 (cells/ μ L) | | (n) | pVL (copies/mL) | |
|----------------|-------------------------|--------------|-----|------|--------|--------|----------|-----|----------------------|-------------|-----|-----------------|------------|
| | | | | | | Median | (Q1, Q3) | | Median | (Q1, Q3) | | Median | (Q1, Q3) |
| Pre-1993 | 30 | 47 | 184 | 175 | 9 | 34 | (30, 39) | 93 | 560 | (400, 800) | 171 | <40 | (<40, <40) |
| 1993 | 29 | 118 | 119 | 105 | 14 | 34 | (29, 40) | 71 | 630 | (415, 815) | 110 | <40 | (<40, <40) |
| 1994 | 28 | 75 | 75 | 64 | 11 | 33 | (29, 37) | 46 | 545 | (345, 790) | 66 | <40 | (<40, <40) |
| 1995 | 28 | 127 | 127 | 108 | 19 | 34 | (29, 39) | 78 | 575 | (415, 795) | 116 | <40 | (<40, <40) |
| 1996 | 26 | 320 | 322 | 277 | 45 | 35 | (30, 39) | 190 | 610 | (403, 830) | 298 | <40 | (<40, <40) |
| 1997 | 24 | 261 | 267 | 242 | 25 | 34 | (30, 38) | 163 | 600 | (385, 850) | 244 | <40 | (<40, <40) |
| 1998 | 23 | 192 | 201 | 168 | 33 | 34 | (30, 40) | 132 | 570 | (420, 813) | 173 | <40 | (<40, <40) |
| 1999 | 23 | 171 | 172 | 134 | 38 | 36 | (30, 42) | 123 | 560 | (395, 820) | 153 | <40 | (<40, <40) |
| 2000 | 24 | 123 | 126 | 103 | 23 | 38 | (34, 44) | 81 | 580 | (370, 740) | 111 | <40 | (<40, <40) |
| 2001 | 23 | 120 | 123 | 99 | 24 | 37 | (32, 44) | 77 | 630 | (400, 840) | 103 | <40 | (<40, <40) |
| 2002 | 22 | 117 | 126 | 109 | 17 | 40 | (31, 46) | 79 | 530 | (370, 717) | 111 | <40 | (<40, <40) |
| 2003 | 21 | 140 | 150 | 128 | 22 | 39 | (34, 46) | 99 | 610 | (432, 805) | 132 | <40 | (<40, <40) |
| 2004 | 20 | 144 | 166 | 130 | 36 | 39 | (34, 44) | 111 | 650 | (455, 850) | 140 | <40 | (<40, <40) |
| 2005 | 19 | 182 | 200 | 159 | 41 | 41 | (35, 47) | 142 | 665 | (470, 895) | 179 | <40 | (<40, <40) |
| 2006 | 18 | 178 | 197 | 158 | 39 | 42 | (33, 47) | 133 | 606 | (480, 800) | 168 | <40 | (<40, <40) |
| 2007 | 17 | 235 | 253 | 218 | 35 | 41 | (35, 46) | 175 | 660 | (470, 885) | 219 | <40 | (<40, <40) |
| 2008 | 16 | 277 | 309 | 255 | 54 | 42 | (35, 49) | 226 | 660 | (493, 920) | 276 | <40 | (<40, <40) |
| 2009 | 15 | 303 | 336 | 276 | 60 | 41 | (35, 47) | 228 | 664 | (480, 910) | 312 | <40 | (<40, <40) |
| 2010 | 14 | 265 | 304 | 243 | 61 | 40 | (32, 46) | 217 | 660 | (450, 840) | 270 | <40 | (<40, <40) |
| 2011 | 13 | 315 | 359 | 292 | 67 | 41 | (34, 48) | 236 | 705 | (490, 913) | 318 | <40 | (<40, <40) |
| 2012 | 12 | 273 | 309 | 247 | 62 | 41 | (32, 49) | 195 | 720 | (530, 990) | 268 | <40 | (<40, <40) |
| 2013 | 11 | 250 | 297 | 234 | 63 | 40 | (32, 48) | 202 | 685 | (460, 890) | 260 | <40 | (<40, <40) |
| 2014 | 10 | 231 | 300 | 258 | 42 | 40 | (31, 50) | 189 | 770 | (520, 990) | 255 | <40 | (<40, <40) |
| 2015 | 9 | 201 | 287 | 246 | 41 | 41 | (31, 51) | 193 | 680 | (490, 910) | 251 | <40 | (<40, <40) |
| 2016 | 8 | 182 | 257 | 212 | 45 | 38 | (32, 49) | 179 | 650 | (480, 910) | 228 | <40 | (<40, <40) |
| 2017 | 8 | 160 | 228 | 196 | 32 | 36 | (28, 45) | 157 | 680 | (480, 860) | 201 | <40 | (<40, <40) |
| 2018 | 7 | 132 | 203 | 160 | 43 | 39 | (31, 48) | 139 | 780 | (560, 1010) | 173 | <40 | (<40, <40) |
| 2019 | 6 | 129 | 242 | 203 | 39 | 38 | (29, 48) | 178 | 720 | (480, 930) | 206 | <40 | (<40, <40) |
| 2020 | 5 | 107 | 205 | 154 | 51 | 37 | (31, 48) | 157 | 760 | (520, 960) | 170 | <40 | (<40, <40) |

Duration defined as cumulative years on antiretroviral treatment, excluding periods of treatment interruption
 CD4 and pVL tests defined as most recent test done in the last 12 months and last 6 months, respectively





2.1 Active participants by Year of Program Initiation (1987 - 2025) - as of February 2025 (cont.)

| DTP Start Year | Duration (years) Median | First Starts | All | Male | Female | Age | | (n) | CD4 (cells/ μ L) | | (n) | pVL (copies/mL) | |
|----------------|-------------------------|--------------|-------------|-------------|-------------|--------|----------|-----|----------------------|------------|-----|-----------------|------------|
| | | | | | | Median | (Q1, Q3) | | Median | (Q1, Q3) | | Median | (Q1, Q3) |
| 2021 | 4 | 111 | 205 | 175 | 30 | 37 | (30, 46) | 179 | 670 | (490, 870) | 145 | <40 | (<40, <40) |
| 2022 | 3 | 113 | 273 | 224 | 49 | 38 | (30, 47) | 248 | 695 | (530, 908) | 210 | <40 | (<40, <40) |
| 2023 | 2 | 117 | 318 | 263 | 55 | 35 | (30, 45) | 299 | 600 | (430, 820) | 244 | <40 | (<40, <40) |
| 2024 | 1 | 137 | 367 | 294 | 73 | 35 | (29, 45) | 347 | 598 | (400, 820) | 341 | <40 | (<40, <40) |
| 2025 | 0 | 23 | 66 | 49 | 17 | 36 | (30, 45) | 63 | 591 | (343, 763) | 60 | <40 | (<40, 92) |
| Total: | | 5876 | 7673 | 6358 | 1315 | | | | | | | | |

Duration defined as cumulative years on antiretroviral treatment, excluding periods of treatment interruption
CD4 and pVL tests defined as most recent test done in the last 12 months and last 6 months, respectively



2.2 HIV Viral Load (copies/mL) and CD4 (cells/ μ L) for Participants on Antiretroviral Treatment

| MON-YYYY | Total Participants | Median # of Treatment days | (n) | CD4 (cells/ μ L) | | (n) | pVL (copies/mL) | |
|----------|--------------------|----------------------------|------|----------------------|------------|------|-----------------|------------|
| | | | | Median | (Q1, Q3) | | Median | (Q1, Q3) |
| MAR-2023 | 7548 | 803 | 5614 | 640 | (460, 860) | 6805 | <40 | (<40, <40) |
| APR-2023 | 7553 | 796 | 5597 | 640 | (460, 860) | 6836 | <40 | (<40, <40) |
| MAY-2023 | 7592 | 786 | 5598 | 640 | (451, 860) | 6873 | <40 | (<40, <40) |
| JUN-2023 | 7599 | 787 | 5591 | 640 | (450, 860) | 6918 | <40 | (<40, <40) |
| JUL-2023 | 7577 | 805 | 5549 | 650 | (450, 860) | 6937 | <40 | (<40, <40) |
| AUG-2023 | 7600 | 804 | 5524 | 641 | (450, 860) | 6890 | <40 | (<40, <40) |
| SEP-2023 | 7609 | 796 | 5485 | 650 | (450, 860) | 6893 | <40 | (<40, <40) |
| OCT-2023 | 7610 | 803 | 5455 | 640 | (450, 860) | 6812 | <40 | (<40, <40) |
| NOV-2023 | 7612 | 795 | 5405 | 640 | (450, 860) | 6840 | <40 | (<40, <40) |
| DEC-2023 | 7603 | 798 | 5387 | 650 | (460, 860) | 6828 | <40 | (<40, <40) |
| JAN-2024 | 7642 | 792 | 5362 | 640 | (460, 860) | 6814 | <40 | (<40, <40) |
| FEB-2024 | 7647 | 781 | 5329 | 650 | (460, 870) | 6864 | <40 | (<40, <40) |
| MAR-2024 | 7636 | 790 | 5326 | 640 | (450, 870) | 6871 | <40 | (<40, <40) |
| APR-2024 | 7670 | 786 | 5310 | 640 | (450, 870) | 6842 | <40 | (<40, <40) |
| MAY-2024 | 7687 | 787 | 5318 | 650 | (460, 880) | 6896 | <40 | (<40, <40) |
| JUN-2024 | 7687 | 784 | 5305 | 650 | (460, 870) | 6921 | <40 | (<40, <40) |
| JUL-2024 | 7718 | 786 | 5334 | 650 | (460, 870) | 7009 | <40 | (<40, <40) |
| AUG-2024 | 7709 | 782 | 5311 | 650 | (460, 870) | 6937 | <40 | (<40, <40) |
| SEP-2024 | 7697 | 791 | 5303 | 650 | (460, 870) | 6904 | <40 | (<40, <40) |
| OCT-2024 | 7725 | 787 | 5314 | 650 | (460, 870) | 6898 | <40 | (<40, <40) |
| NOV-2024 | 7703 | 793 | 5308 | 650 | (460, 880) | 6875 | <40 | (<40, <40) |
| DEC-2024 | 7720 | 796 | 5326 | 650 | (460, 880) | 6913 | <40 | (<40, <40) |
| JAN-2025 | 7739 | 792 | 5331 | 650 | (450, 880) | 6882 | <40 | (<40, <40) |
| FEB-2025 | 7696 | 800 | 5304 | 650 | (460, 880) | 6870 | <40 | (<40, <40) |

Active participant defined as being on antiretroviral treatment in the specified month

Treatment days defined as number of consecutive days on antiretroviral treatment (most recent uninterrupted period)

CD4 and pVL tests defined as tests done in the specified month



2.3 BC-CfE HIV Treatment Program Enrolment

| MON-YYYY | On ARV Treatment | Off ARV Treatment | Deceased | ARV Treatment naïve starts | ARV Treatment experienced starts | Newly interrupted ARV Treatment | Net Change |
|----------|------------------|-------------------|----------|----------------------------|----------------------------------|---------------------------------|------------|
| MAR-2023 | 7532 | 742 | 15 | 17 | 201 | 176 | 27 |
| APR-2023 | 7531 | 748 | 13 | 10 | 177 | 169 | -1 |
| MAY-2023 | 7574 | 714 | 7 | 14 | 206 | 165 | 43 |
| JUN-2023 | 7577 | 697 | 14 | 17 | 168 | 165 | 3 |
| JUL-2023 | 7555 | 728 | 11 | 11 | 164 | 181 | -22 |
| AUG-2023 | 7577 | 727 | 11 | 13 | 217 | 192 | 22 |
| SEP-2023 | 7579 | 714 | 14 | 5 | 179 | 163 | 2 |
| OCT-2023 | 7579 | 724 | 18 | 10 | 170 | 160 | 0 |
| NOV-2023 | 7578 | 731 | 18 | 9 | 182 | 171 | -1 |
| DEC-2023 | 7574 | 740 | 14 | 13 | 169 | 169 | -4 |
| JAN-2024 | 7613 | 698 | 16 | 11 | 204 | 159 | 39 |
| FEB-2024 | 7620 | 695 | 17 | 11 | 184 | 165 | 7 |
| MAR-2024 | 7616 | 709 | 12 | 13 | 183 | 185 | -4 |
| APR-2024 | 7647 | 692 | 17 | 20 | 197 | 168 | 31 |
| MAY-2024 | 7666 | 691 | 12 | 16 | 191 | 173 | 19 |
| JUN-2024 | 7678 | 706 | 5 | 23 | 173 | 177 | 12 |
| JUL-2024 | 7697 | 695 | 15 | 10 | 185 | 159 | 19 |
| AUG-2024 | 7686 | 710 | 13 | 15 | 164 | 168 | -11 |
| SEP-2024 | 7674 | 716 | 9 | 7 | 182 | 186 | -12 |
| OCT-2024 | 7702 | 709 | 8 | 15 | 200 | 172 | 28 |
| NOV-2024 | 7674 | 746 | 14 | 9 | 181 | 199 | -28 |
| DEC-2024 | 7693 | 743 | 15 | 10 | 194 | 170 | 19 |
| JAN-2025 | 7712 | 716 | 14 | 14 | 196 | 170 | 19 |
| FEB-2025 | 7673 | 759 | 10 | 9 | 166 | 201 | -39 |

ARV: antiretroviral

On ARV Treatment: based on dispensing data, participants with a record of ARV medication in the specified month and not deceased or moved out of program

Off ARV Treatment: based on dispensing data, participants with no record of ARV medication in the specified month and not deceased or moved out of program

Deceased: in the specified month, and on ARV treatment in the previous month

ARV Treatment naïve starts: participants starting ARV treatment in the specified month for the first time

ARV Treatment experienced starts: participants with history of ARV treatment, but first dispensing in the BC HIV Treatment Program in the specified month


Newly Interrupted ARV Treatment: based on dispensing data, participants with no record of ARV medication in the specified month, but had a record of ARV medication in the previous month, and not deceased or moved out of program, and had contact with the program in the past 5 years.

Net Change: the difference between ARV treatment starts (naïve and experienced) and ARV treatment stops (Deceased, moved out of program, or newly interrupted ARV treatment)






3.1 Distribution of HIV Treatment Program Active Participants February 2025






3.2 Distribution of HIV Treatment Program Active Participants February 2025

INTERIOR HEALTH AUTHORITY BY HEALTH SERVICE DELIVERY AREA/LOCAL HEALTH AREA




KELOWNA BY POSTAL CODE






3.3 Distribution of HIV Treatment Program Active Participants February 2025

FRASER HEALTH AUTHORITY BY HEALTH SERVICE DELIVERY AREA/LOCAL HEALTH AREA




SURREY BY POSTAL CODE




3.4 Distribution of HIV Treatment Program Active Participants February 2025

VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICE DELIVERY AREA/LOCAL HEALTH AREA



VANCOUVER BY POSTAL CODE




*** Please refer to VIHA (432 and 434) on the next page






3.5 Distribution of HIV Treatment Program Active Participants February 2025

VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICE DELIVERY AREA/LOCAL HEALTH AREA




VICTORIA BY POSTAL CODE






3.6 Distribution of HIV Treatment Program Active Participants February 2025

NORTHERN HEALTH AUTHORITY BY HEALTH SERVICE DELIVERY AREA/LOCAL HEALTH AREA



PRINCE GEORGE BY POSTAL CODE



4.1 Distribution of Participants by Age & Sex at Birth INTERIOR Health Authority (HA)

| Health Service Delivery Area | Age Group | # Enrolled | # on ART | # First Starts | # CD4 Tested | Median CD4 | # pVL Tested | Median pVL |
|------------------------------|--------------------|------------|------------|----------------|--------------|------------|--------------|---------------|
| EAST KOOTENAY | 0 - 29 | * | * | 0 | 0 | N/A | * | * |
| | 30 - 49 | * | * | 0 | 9 | 840 | * | * |
| | 50 - 64 | * | * | 0 | 14 | 750 | * | * |
| | 65+ | * | * | 0 | 7 | 650 | * | * |
| | Total HSDA: | 36 | 31 | 0 | 30 | 755 | 29 | <40 |
| KOOTENAY BOUNDARY | 0 - 29 | 5 | 5 | 0 | * | * | * | * |
| | 30 - 49 | 15 | 14 | 0 | * | * | * | * |
| | 50 - 64 | 23 | 20 | 0 | * | * | * | * |
| | 65+ | 16 | 16 | 0 | * | * | * | * |
| | Total HSDA: | 59 | 55 | 0 | 44 | 725 | 45 | <40 |
| OKANAGAN | 0 - 29 | 14 | 14 | 0 | 14 | 830 | 12 | <40 |
| | 30 - 49 | 127 | 118 | 0 | 116 | 700 | 102 | <40 |
| | 50 - 64 | 163 | 152 | 0 | 146 | 690 | 127 | <40 |
| | 65+ | 80 | 77 | 0 | 75 | 540 | 68 | <40 |
| | Total HSDA: | 384 | 361 | 0 | 351 | 660 | 309 | <40 |
| THOMPSON/CARIBOO/SHUSWAP | 0 - 29 | 12 | 9 | * | 9 | 740 | 9 | <40 |
| | 30 - 49 | 53 | 42 | * | 41 | 720 | 38 | <40 |
| | 50 - 64 | 87 | 76 | * | 69 | 550 | 66 | <40 |
| | 65+ | 37 | 37 | * | 29 | 620 | 33 | <40 |
| | Total HSDA: | 189 | 164 | <5 | 148 | 660 | 146 | <40 |
| Total HA: | | 668 | 611 | <5 | 573 | 670 | 529 | <40 |

| | Age Group | # Enrolled | # on ART | # First Starts | # CD4 Tested | Median CD4 | # pVL Tested | Median pVL |
|------------------|-----------|------------|------------|----------------|--------------|------------|--------------|---------------|
| | 0 - 29 | 32 | 29 | * | 27 | 800 | 26 | <40 |
| | 30 - 49 | 209 | 185 | * | 176 | 715 | 162 | <40 |
| | 50 - 64 | 287 | 260 | * | 247 | 680 | 221 | <40 |
| | 65+ | 140 | 137 | * | 123 | 570 | 120 | <40 |
| Total HA: | | 668 | 611 | <5 | 573 | 670 | 529 | <40 |

| Sex at Birth | # Enrolled | # on ART | # First Starts | # CD4 Tested | Median CD4 | # pVL Tested | Median pVL |
|--------------|------------|----------|----------------|--------------|------------|--------------|------------|
| Male | 538 | 494 | * | 458 | 660 | 425 | <40 |
| Female | 130 | 117 | * | 115 | 700 | 104 | <40 |
| Unknown | 0 | 0 | * | 0 | N/A | 0 | N/A |

| Currently on antiretroviral treatment | # of Participants | Median Age | Median CD4 | Median pVL |
|---------------------------------------|-------------------|------------|------------|---------------|
| Total HA: | 611 | 56 | 675 | <40 |

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Enrolled: Participants who had enrolled in the HIV Treatment Program, but not known to be deceased or formally reported as moved out of program
 # **on ART:** # of participants on antiretroviral treatment (ART) in the specified month based on dispensing record
 # **CD4 or pVL tested:** participants tested for CD4 or pVL within the past 12 months and 6 months, respectively (CD4 in cells/μL and pVL in copies/mL)



4.2 Distribution of Participants by Program Duration INTERIOR Health Authority

| HSDA | Program Duration | # Enrolled | # on ART | # First Starts | # CD4 Tested | Median CD4 | # pVL Tested | Median pVL |
|--------------------------|--------------------|------------|------------|----------------|--------------|------------|--------------|---------------|
| EAST KOOTENAY | 10 years or more | 16 | 13 | 0 | 14 | 710 | 12 | <40 |
| | 5 years or more | 10 | 9 | 0 | 8 | 865 | 8 | <40 |
| | <5 years | 10 | 9 | 0 | 8 | 855 | 9 | <40 |
| | Never on ART | 0 | 0 | 0 | 0 | N/A | 0 | N/A |
| | Total HSDA: | 36 | 31 | 0 | 30 | 755 | 29 | <40 |
| KOOTENAY BOUNDARY | 10 years or more | 42 | 40 | 0 | 32 | 665 | 31 | <40 |
| | 5 years or more | 10 | 8 | 0 | 5 | 780 | 7 | <40 |
| | <5 years | 7 | 7 | 0 | 7 | 750 | 7 | <40 |
| | Never on ART | 0 | 0 | 0 | 0 | N/A | 0 | N/A |
| | Total HSDA: | 59 | 55 | 0 | 44 | 725 | 45 | <40 |
| OKANAGAN | 10 years or more | 244 | 233 | 0 | 217 | 670 | 196 | <40 |
| | 5 years or more | 62 | 57 | 0 | 55 | 690 | 49 | <40 |
| | <5 years | 78 | 71 | 0 | 79 | 610 | 64 | <40 |
| | Never on ART | 0 | 0 | 0 | 0 | N/A | 0 | N/A |
| | Total HSDA: | 384 | 361 | 0 | 351 | 660 | 309 | <40 |
| THOMPSON/CARIBOO/SHUSWAP | 10 years or more | 119 | 105 | * | 96 | 630 | 97 | <40 |
| | 5 years or more | 26 | 21 | * | 15 | 700 | 17 | <40 |
| | <5 years | 44 | 38 | * | 37 | 680 | 32 | <40 |
| | Never on ART | 0 | 0 | * | 0 | N/A | 0 | N/A |
| | Total HSDA: | 189 | 164 | <5 | 148 | 660 | 146 | <40 |
| Total HA: | | 668 | 611 | <5 | 573 | 670 | 529 | <40 |

| | Program Duration | # Enrolled | # on ART | # First Starts | # CD4 Tested | Median CD4 | # pVL Tested | Median pVL |
|------------------|------------------|------------|------------|----------------|--------------|------------|--------------|---------------|
| | 10 years or more | 421 | 391 | * | 359 | 670 | 336 | <40 |
| | 5 years or more | 108 | 95 | * | 83 | 710 | 81 | <40 |
| | <5 years | 139 | 125 | * | 131 | 650 | 112 | <40 |
| | Never on ART | 0 | 0 | * | 0 | N/A | 0 | N/A |
| Total HA: | | 668 | 611 | <5 | 573 | 670 | 529 | <40 |

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Enrolled: Participants who had enrolled in HIV Treatment Program, not known to be deceased or formally reported as moved out of program

on ART: Participants on antiretroviral treatment (ART) in the specified month based on dispensing record (as above footnote)

Program Duration: years since first antiretroviral treatment dispensing in BC HIV Treatment Program

CD4 or pVL tested: participants tested for CD4 or pVL within the past 12 months and 6 months, respectively





4.3 Distribution of Antiretroviral Treatment Prescribers INTERIOR Health Authority

| HSDA of Prescriber Residency | # of Prescribers currently prescribing Antiretroviral Treatment | # of Participants currently treated by Prescribers | # of Prescribers ever prescribed Antiretroviral Treatment | # of Participants ever treated by Prescribers |
|------------------------------|---|--|---|---|
| EAST KOOTENAY | 13 | 32 | 53 | 102 |
| KOOTENAY BOUNDARY | 18 | 40 | 76 | 140 |
| OKANAGAN | 55 | 335 | 245 | 1108 |
| THOMPSON/CARIBOO/SHUSWAP | 30 | 135 | 151 | 588 |
| Total: | 116 | 542 | 525 | 1938 |

| HSDA of Participant Residency | # of Participants with Prescriber out of HA/HSDA |
|-------------------------------|--|
| EAST KOOTENAY | * |
| KOOTENAY BOUNDARY | * |
| OKANAGAN | * |
| THOMPSON/CARIBOO/SHUSWAP | * |
| Total: | 125 |

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Currently prescribing Antiretroviral Treatment: number of prescribers of antiretroviral treatment dispensed in the previous 6 months (based on participant HA/HSDA)

Currently treated: number of participants with antiretroviral treatment dispensed in the previous 6 months by antiretroviral treatment prescribers (based on follow-up prescriber HA/HSDA)

Prescribers ever prescribed Antiretroviral Treatment: for participants residing in HA/HSDA

Participants ever treated by prescribers: where follow-up prescriber is in the HA/HSDA

Participants with Prescriber out of HA/HSDA: participants residing in specified HA/HSDA with follow-up prescriber(s) in another HA/HSDA





4.4 Distribution of Participants by Age & Sex at Birth FRASER Health Authority (HA)

| Health Service Delivery Area | Age Group | # Enrolled | # on ART | # First Starts | # CD4 Tested | Median CD4 | # pVL Tested | Median pVL |
|------------------------------|--------------------|-------------|-------------|----------------|--------------|------------|--------------|---------------|
| FRASER EAST | 0 - 29 | 35 | 30 | * | 31 | 770 | 33 | <40 |
| | 30 - 49 | 108 | 88 | * | 83 | 680 | 79 | <40 |
| | 50 - 64 | 152 | 138 | * | 107 | 594 | 130 | <40 |
| | 65+ | 74 | 71 | * | 50 | 710 | 68 | <40 |
| | Total HSDA: | 369 | 327 | <5 | 271 | 680 | 310 | <40 |
| FRASER NORTH | 0 - 29 | 50 | 44 | 0 | 44 | 645 | 45 | <40 |
| | 30 - 49 | 369 | 326 | 0 | 302 | 710 | 323 | <40 |
| | 50 - 64 | 369 | 339 | 0 | 253 | 700 | 327 | <40 |
| | 65+ | 166 | 156 | 0 | 104 | 660 | 144 | <40 |
| | Total HSDA: | 954 | 865 | 0 | 703 | 690 | 839 | <40 |
| FRASER SOUTH | 0 - 29 | 66 | 62 | 0 | 62 | 600.5 | 64 | <40 |
| | 30 - 49 | 353 | 329 | 0 | 257 | 700 | 305 | <40 |
| | 50 - 64 | 395 | 368 | 0 | 261 | 630 | 331 | <40 |
| | 65+ | 161 | 156 | 0 | 110 | 570 | 151 | <40 |
| | Total HSDA: | 975 | 915 | 0 | 690 | 648 | 851 | <40 |
| Total HA: | | 2298 | 2107 | <5 | 1664 | 670 | 2000 | <40 |

| | Age Group | # Enrolled | # on ART | # First Starts | # CD4 Tested | Median CD4 | # pVL Tested | Median pVL |
|------------------|-----------|-------------|-------------|----------------|--------------|------------|--------------|---------------|
| | 0 - 29 | 151 | 136 | * | 137 | 660 | 142 | <40 |
| | 30 - 49 | 830 | 743 | * | 642 | 700 | 707 | <40 |
| | 50 - 64 | 916 | 845 | * | 621 | 650 | 788 | <40 |
| | 65+ | 401 | 383 | * | 264 | 610 | 363 | <40 |
| Total HA: | | 2298 | 2107 | <5 | 1664 | 670 | 2000 | <40 |

| Sex at Birth | # Enrolled | # on ART | # First Starts | # CD4 Tested | Median CD4 | # pVL Tested | Median pVL |
|--------------|------------|----------|----------------|--------------|------------|--------------|------------|
| Male | 1735 | 1606 | * | 1207 | 650 | 1533 | <40 |
| Female | 563 | 501 | * | 457 | 720 | 467 | <40 |
| Unknown | 0 | 0 | * | 0 | N/A | 0 | N/A |

| Currently on antiretroviral treatment | # of Participants | Median Age | Median CD4 | Median pVL |
|---------------------------------------|-------------------|------------|------------|---------------|
| Total HA: | 2107 | 53 | 673 | <40 |

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Enrolled: Participants who had enrolled in the HIV Treatment Program, but not known to be deceased or formally reported as moved out of program
 # **on ART:** # of participants on antiretroviral treatment (ART) in the specified month based on dispensing record
 # **CD4 or pVL tested:** participants tested for CD4 or pVL within the past 12 months and 6 months, respectively (CD4 in cells/μL and pVL in copies/mL)



4.5 Distribution of Participants by Program Duration FRASER Health Authority

| HSDA | Program Duration | # Enrolled | # on ART | # First Starts | # CD4 Tested | Median CD4 | # pVL Tested | Median pVL |
|------------------|--------------------|-------------|-------------|----------------|--------------|------------|--------------|---------------|
| FRASER EAST | 10 years or more | 232 | 215 | * | * | * | * | * |
| | 5 years or more | 59 | 42 | * | * | * | * | * |
| | <5 years | 78 | 70 | * | * | * | * | * |
| | Never on ART | 0 | 0 | * | * | * | * | * |
| | Total HSDA: | 369 | 327 | <5 | 271 | 680 | 310 | <40 |
| FRASER NORTH | 10 years or more | 590 | 541 | 0 | * | * | * | * |
| | 5 years or more | 174 | 155 | 0 | * | * | * | * |
| | <5 years | 190 | 169 | 0 | * | * | * | * |
| | Never on ART | 0 | 0 | 0 | * | * | * | * |
| | Total HSDA: | 954 | 865 | 0 | 703 | 690 | 839 | <40 |
| FRASER SOUTH | 10 years or more | 569 | 532 | 0 | * | * | * | * |
| | 5 years or more | 170 | 153 | 0 | * | * | * | * |
| | <5 years | 236 | 230 | 0 | * | * | * | * |
| | Never on ART | 0 | 0 | 0 | * | * | * | * |
| | Total HSDA: | 975 | 915 | 0 | 690 | 648 | 851 | <40 |
| Total HA: | | 2298 | 2107 | <5 | 1664 | 670 | 2000 | <40 |

| | Program Duration | # Enrolled | # on ART | # First Starts | # CD4 Tested | Median CD4 | # pVL Tested | Median pVL |
|------------------|------------------|-------------|-------------|----------------|--------------|------------|--------------|---------------|
| | 10 years or more | 1391 | 1288 | * | 951 | 690 | 1204 | <40 |
| | 5 years or more | 403 | 350 | * | 284 | 675 | 327 | <40 |
| | <5 years | 504 | 469 | * | 424 | 627 | 463 | <40 |
| | Never on ART | 0 | 0 | * | 5 | 560 | 6 | 78 |
| Total HA: | | 2298 | 2107 | <5 | 1664 | 670 | 2000 | <40 |

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Enrolled: Participants who had enrolled in HIV Treatment Program, not known to be deceased or formally reported as moved out of program

on ART: Participants on antiretroviral treatment (ART) in the specified month based on dispensing record (as above footnote)

Program Duration: years since first antiretroviral treatment dispensing in BC HIV Treatment Program

CD4 or pVL tested: participants tested for CD4 or pVL within the past 12 months and 6 months, respectively





4.6 Distribution of Antiretroviral Treatment Prescribers FRASER Health Authority

| HSDA of Prescriber Residency | # of Prescribers currently prescribing Antiretroviral Treatment | # of Participants currently treated by Prescribers | # of Prescribers ever prescribed Antiretroviral Treatment | # of Participants ever treated by Prescribers |
|------------------------------|---|--|---|---|
| FRASER EAST | 32 | 65 | 154 | 554 |
| FRASER NORTH | 32 | 245 | 268 | 1653 |
| FRASER SOUTH | 43 | 546 | 237 | 1952 |
| Total: | 107 | 856 | 659 | 4159 |

| HSDA of Participant Residency | # of Participants with Prescriber out of HA/HSDA |
|-------------------------------|--|
| FRASER EAST | 217 |
| FRASER NORTH | 717 |
| FRASER SOUTH | 484 |
| Total: | 1418 |

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Currently prescribing Antiretroviral Treatment: number of prescribers of antiretroviral treatment dispensed in the previous 6 months (based on participant HA/HSDA)

Currently treated: number of participants with antiretroviral treatment dispensed in the previous 6 months by antiretroviral treatment prescribers (based on follow-up prescriber HA/HSDA)

Prescribers ever prescribed Antiretroviral Treatment: for participants residing in HA/HSDA

Participants ever treated by prescribers: where follow-up prescriber is in the HA/HSDA

Participants with Prescriber out of HA/HSDA: participants residing in specified HA/HSDA with follow-up prescriber(s) in another HA/HSDA



4.7 Distribution of Participants by Age & Sex at Birth VANCOUVER COASTAL Health Authority (HA)

| Health Service Delivery Area | Age Group | # Enrolled | # on ART | # First Starts | # CD4 Tested | Median CD4 | # pVL Tested | Median pVL |
|------------------------------|--------------------|-------------|-------------|----------------|--------------|------------|--------------|---------------|
| NORTH SHORE/COAST GARIBALDI | 0 - 29 | 12 | 12 | 0 | 10 | 855 | 11 | <40 |
| | 30 - 49 | 83 | 77 | 0 | 60 | 680 | 65 | <40 |
| | 50 - 64 | 130 | 119 | 0 | 84 | 710 | 102 | <40 |
| | 65+ | 93 | 89 | 0 | 73 | 620 | 84 | <40 |
| | Total HSDA: | 318 | 297 | 0 | 227 | 690 | 262 | <40 |
| RICHMOND | 0 - 29 | 12 | 10 | * | 12 | 585 | 10 | <40 |
| | 30 - 49 | 65 | 55 | * | 55 | 610 | 56 | <40 |
| | 50 - 64 | 76 | 72 | * | 59 | 640 | 70 | <40 |
| | 65+ | 30 | 30 | * | 26 | 538.5 | 30 | <40 |
| | Total HSDA: | 183 | 167 | <5 | 152 | 600 | 166 | <40 |
| VANCOUVER | 0 - 29 | 113 | 96 | * | 99 | 740 | 101 | <40 |
| | 30 - 49 | 1136 | 989 | * | 815 | 680 | 954 | <40 |
| | 50 - 64 | 1528 | 1404 | * | 1052 | 600 | 1367 | <40 |
| | 65+ | 725 | 697 | * | 451 | 610 | 689 | <40 |
| | Total HSDA: | 3502 | 3186 | <5 | 2417 | 640 | 3111 | <40 |
| Total HA: | | 4003 | 3650 | <5 | 2796 | 640 | 3539 | <40 |

| | Age Group | # Enrolled | # on ART | # First Starts | # CD4 Tested | Median CD4 | # pVL Tested | Median pVL |
|------------------|-----------|-------------|-------------|----------------|--------------|------------|--------------|---------------|
| | 0 - 29 | 137 | 118 | * | 121 | 730 | 122 | <40 |
| | 30 - 49 | 1284 | 1121 | * | 930 | 680 | 1075 | <40 |
| | 50 - 64 | 1734 | 1595 | * | 1195 | 610 | 1539 | <40 |
| | 65+ | 848 | 816 | * | 550 | 605 | 803 | <40 |
| Total HA: | | 4003 | 3650 | <5 | 2796 | 640 | 3539 | <40 |

| Sex at Birth | # Enrolled | # on ART | # First Starts | # CD4 Tested | Median CD4 | # pVL Tested | Median pVL |
|--------------|------------|----------|----------------|--------------|------------|--------------|------------|
| Male | 3514 | 3204 | * | 2346 | 640 | 3139 | <40 |
| Female | 489 | 446 | * | 450 | 650 | 400 | <40 |
| Unknown | 0 | 0 | * | 0 | N/A | 0 | N/A |

| Currently on antiretroviral treatment | # of Participants | Median Age | Median CD4 | Median pVL |
|---------------------------------------|-------------------|------------|------------|---------------|
| Total HA: | 3650 | 56 | 650 | <40 |

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Enrolled: Participants who had enrolled in the HIV Treatment Program, but not known to be deceased or formally reported as moved out of program
 # **on ART**: # of participants on antiretroviral treatment (ART) in the specified month based on dispensing record
 # **CD4** or **pVL** tested: participants tested for CD4 or pVL within the past 12 months and 6 months, respectively (CD4 in cells/ μ L and pVL in copies/mL)



4.8 Distribution of Participants by Program Duration VANCOUVER COASTAL Health Authority

| HSDA | Program Duration | # Enrolled | # on ART | # First Starts | # CD4 Tested | Median CD4 | # pVL Tested | Median pVL |
|-----------------------------|--------------------|-------------|-------------|----------------|--------------|------------|--------------|---------------|
| NORTH SHORE/COAST GARIBALDI | 10 years or more | 227 | 210 | 0 | * | * | * | * |
| | 5 years or more | 45 | 44 | 0 | * | * | * | * |
| | <5 years | 46 | 43 | 0 | * | * | * | * |
| | Never on ART | 0 | 0 | 0 | * | * | * | * |
| | Total HSDA: | 318 | 297 | 0 | 227 | 690 | 262 | <40 |
| RICHMOND | 10 years or more | 101 | 94 | * | 76 | 625 | 91 | <40 |
| | 5 years or more | 34 | 28 | * | 28 | 600 | 29 | <40 |
| | <5 years | 48 | 45 | * | 48 | 595 | 46 | <40 |
| | Never on ART | 0 | 0 | * | 0 | N/A | 0 | N/A |
| | Total HSDA: | 183 | 167 | <5 | 152 | 600 | 166 | <40 |
| VANCOUVER | 10 years or more | 2443 | 2260 | * | * | * | * | * |
| | 5 years or more | 554 | 468 | * | * | * | * | * |
| | <5 years | 505 | 458 | * | * | * | * | * |
| | Never on ART | 0 | 0 | * | * | * | * | * |
| | Total HSDA: | 3502 | 3186 | <5 | 2417 | 640 | 3111 | <40 |
| Total HA: | | 4003 | 3650 | <5 | 2796 | 640 | 3539 | <40 |

| | Program Duration | # Enrolled | # on ART | # First Starts | # CD4 Tested | Median CD4 | # pVL Tested | Median pVL |
|------------------|------------------|-------------|-------------|----------------|--------------|------------|--------------|---------------|
| | 10 years or more | 2771 | 2564 | * | 1851 | 620 | * | * |
| | 5 years or more | 633 | 540 | * | 429 | 700 | * | * |
| | <5 years | 599 | 546 | * | 511 | 670 | * | * |
| | Never on ART | 0 | 0 | * | 5 | 880 | * | * |
| Total HA: | | 4003 | 3650 | <5 | 2796 | 640 | 3539 | <40 |

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Enrolled: Participants who had enrolled in HIV Treatment Program, not known to be deceased or formally reported as moved out of program

on ART: Participants on antiretroviral treatment (ART) in the specified month based on dispensing record (as above footnote)

Program Duration: years since first antiretroviral treatment dispensing in BC HIV Treatment Program

CD4 or pVL tested: participants tested for CD4 or pVL within the past 12 months and 6 months, respectively





4.9 Distribution of Antiretroviral Treatment Prescribers VANCOUVER COASTAL Health Authority

| HSDA of Prescriber Residency | # of Prescribers currently prescribing Antiretroviral Treatment | # of Participants currently treated by Prescribers | # of Prescribers ever prescribed Antiretroviral Treatment | # of Participants ever treated by Prescribers |
|------------------------------|---|--|---|---|
| NORTH SHORE/COAST GARIBALDI | 37 | 58 | 200 | 580 |
| RICHMOND | 9 | 111 | 49 | 339 |
| VANCOUVER | 209 | 5426 | 696 | 12156 |
| Total: | 255 | 5595 | 945 | 13075 |

| HSDA of Participant Residency | # of Participants with Prescriber out of HA/HSDA |
|-------------------------------|--|
| NORTH SHORE/COAST GARIBALDI | * |
| RICHMOND | * |
| VANCOUVER | * |
| Total: | 55 |

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Currently prescribing Antiretroviral Treatment: number of prescribers of antiretroviral treatment dispensed in the previous 6 months (based on participant HA/HSDA)

Currently treated: number of participants with antiretroviral treatment dispensed in the previous 6 months by antiretroviral treatment prescribers (based on follow-up prescriber HA/HSDA)

Prescribers ever prescribed Antiretroviral Treatment: for participants residing in HA/HSDA

Participants ever treated by prescribers: where follow-up prescriber is in the HA/HSDA

Participants with Prescriber out of HA/HSDA: participants residing in specified HA/HSDA with follow-up prescriber(s) in another HA/HSDA



4.10 Distribution of Participants by Age & Sex at Birth VANCOUVER ISLAND Health Authority (HA)

| Health Service Delivery Area | Age Group | # Enrolled | # on ART | # First Starts | # CD4 Tested | Median CD4 | # pVL Tested | Median pVL |
|------------------------------|--------------------|-------------|-------------|----------------|--------------|------------|--------------|---------------|
| CENTRAL VANCOUVER ISLAND | 0 - 29 | 8 | 7 | * | * | * | 6 | <40 |
| | 30 - 49 | 80 | 76 | * | * | * | 67 | <40 |
| | 50 - 64 | 143 | 137 | * | * | * | 109 | <40 |
| | 65+ | 83 | 77 | * | * | * | 76 | <40 |
| | Total HSDA: | 314 | 297 | <5 | 180 | 570 | 258 | <40 |
| NORTH VANCOUVER ISLAND | 0 - 29 | 5 | 5 | 0 | 5 | 760 | * | * |
| | 30 - 49 | 30 | 25 | 0 | 18 | 620 | * | * |
| | 50 - 64 | 56 | 53 | 0 | 30 | 510 | * | * |
| | 65+ | 34 | 33 | 0 | 17 | 580 | * | * |
| | Total HSDA: | 125 | 116 | 0 | 70 | 610 | 96 | <40 |
| SOUTH VANCOUVER ISLAND | 0 - 29 | 27 | 24 | * | 12 | 525 | 17 | <40 |
| | 30 - 49 | 211 | 184 | * | 75 | 690 | 155 | <40 |
| | 50 - 64 | 315 | 295 | * | 92 | 600 | 246 | <40 |
| | 65+ | 157 | 151 | * | 38 | 660 | 141 | <40 |
| | Total HSDA: | 710 | 654 | <5 | 217 | 640 | 559 | <40 |
| Total HA: | | 1149 | 1067 | 5 | 467 | 600 | 913 | <40 |

| | Age Group | # Enrolled | # on ART | # First Starts | # CD4 Tested | Median CD4 | # pVL Tested | Median pVL |
|------------------|-----------|-------------|-------------|----------------|--------------|------------|--------------|---------------|
| | 0 - 29 | 40 | 36 | * | 21 | 600 | 26 | <40 |
| | 30 - 49 | 321 | 285 | * | 148 | 645 | 241 | <40 |
| | 50 - 64 | 514 | 485 | * | 197 | 600 | 403 | <40 |
| | 65+ | 274 | 261 | * | 101 | 560 | 243 | <40 |
| Total HA: | | 1149 | 1067 | 5 | 467 | 600 | 913 | <40 |

| Sex at Birth | # Enrolled | # on ART | # First Starts | # CD4 Tested | Median CD4 | # pVL Tested | Median pVL |
|--------------|------------|----------|----------------|--------------|------------|--------------|------------|
| Male | 957 | 891 | * | 369 | 590 | 755 | <40 |
| Female | 192 | 176 | * | 98 | 685 | 158 | <40 |
| Unknown | 0 | 0 | * | 0 | N/A | 0 | N/A |

| Currently on antiretroviral treatment | # of Participants | Median Age | Median CD4 | Median pVL |
|---------------------------------------|-------------------|------------|------------|---------------|
| Total HA: | 1067 | 57 | 610 | <40 |

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Enrolled: Participants who had enrolled in the HIV Treatment Program, but not known to be deceased or formally reported as moved out of program
on ART: # of participants on antiretroviral treatment (ART) in the specified month based on dispensing record
CD4 or pVL tested: participants tested for CD4 or pVL within the past 12 months and 6 months, respectively (CD4 in cells/ μ L and pVL in copies/mL)



4.11 Distribution of Participants by Program Duration VANCOUVER ISLAND Health Authority

| HSDA | Program Duration | # Enrolled | # on ART | # First Starts | # CD4 Tested | Median CD4 | # pVL Tested | Median pVL |
|--------------------------|--------------------|-------------|-------------|----------------|--------------|------------|--------------|---------------|
| CENTRAL VANCOUVER ISLAND | 10 years or more | 213 | 199 | * | 106 | 590 | 166 | <40 |
| | 5 years or more | 54 | 51 | * | 38 | 580 | 46 | <40 |
| | <5 years | 47 | 47 | * | 36 | 355 | 46 | <40 |
| | Never on ART | 0 | 0 | * | 0 | N/A | 0 | N/A |
| | Total HSDA: | 314 | 297 | <5 | 180 | 570 | 258 | <40 |
| NORTH VANCOUVER ISLAND | 10 years or more | 91 | 85 | 0 | 44 | 515 | 69 | <40 |
| | 5 years or more | 15 | 12 | 0 | 8 | 530 | 12 | <40 |
| | <5 years | 19 | 19 | 0 | 18 | 690 | 15 | <40 |
| | Never on ART | 0 | 0 | 0 | 0 | N/A | 0 | N/A |
| | Total HSDA: | 125 | 116 | 0 | 70 | 610 | 96 | <40 |
| SOUTH VANCOUVER ISLAND | 10 years or more | 431 | 404 | * | * | * | * | * |
| | 5 years or more | 135 | 118 | * | * | * | * | * |
| | <5 years | 144 | 132 | * | * | * | * | * |
| | Never on ART | 0 | 0 | * | * | * | * | * |
| | Total HSDA: | 710 | 654 | <5 | 217 | 640 | 559 | <40 |
| Total HA: | | 1149 | 1067 | 5 | 467 | 600 | 913 | <40 |

| | Program Duration | # Enrolled | # on ART | # First Starts | # CD4 Tested | Median CD4 | # pVL Tested | Median pVL |
|------------------|------------------|-------------|-------------|----------------|--------------|------------|--------------|---------------|
| | 10 years or more | 735 | 688 | 0 | * | * | * | * |
| | 5 years or more | 204 | 181 | 0 | * | * | * | * |
| | <5 years | 210 | 198 | 5 | * | * | * | * |
| | Never on ART | 0 | 0 | 0 | * | * | * | * |
| Total HA: | | 1149 | 1067 | 5 | 467 | 600 | 913 | <40 |

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Enrolled: Participants who had enrolled in HIV Treatment Program, not known to be deceased or formally reported as moved out of program

on ART: Participants on antiretroviral treatment (ART) in the specified month based on dispensing record (as above footnote)

Program Duration: years since first antiretroviral treatment dispensing in BC HIV Treatment Program

CD4 or pVL tested: participants tested for CD4 or pVL within the past 12 months and 6 months, respectively





4.12 Distribution of Antiretroviral Treatment Prescribers VANCOUVER ISLAND Health Authority

| HSDA of Prescriber Residency | # of Prescribers currently prescribing Antiretroviral Treatment | # of Participants currently treated by Prescribers | # of Prescribers ever prescribed Antiretroviral Treatment | # of Participants ever treated by Prescribers |
|------------------------------|---|--|---|---|
| CENTRAL VANCOUVER ISLAND | 68 | 213 | 214 | 978 |
| NORTH VANCOUVER ISLAND | 32 | 68 | 155 | 366 |
| SOUTH VANCOUVER ISLAND | 44 | 609 | 236 | 2066 |
| Total: | 144 | 890 | 605 | 3410 |

| HSDA of Participant Residency | # of Participants with Prescriber out of HA/HSDA |
|-------------------------------|--|
| CENTRAL VANCOUVER ISLAND | 83 |
| NORTH VANCOUVER ISLAND | 53 |
| SOUTH VANCOUVER ISLAND | 132 |
| Total: | 268 |

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Currently prescribing Antiretroviral Treatment: number of prescribers of antiretroviral treatment dispensed in the previous 6 months (based on participant HA/HSDA)

Currently treated: number of participants with antiretroviral treatment dispensed in the previous 6 months by antiretroviral treatment prescribers (based on follow-up prescriber HA/HSDA)

Prescribers ever prescribed Antiretroviral Treatment: for participants residing in HA/HSDA

Participants ever treated by prescribers: where follow-up prescriber is in the HA/HSDA

Participants with Prescriber out of HA/HSDA: participants residing in specified HA/HSDA with follow-up prescriber(s) in another HA/HSDA



4.13 Distribution of Participants by Age & Sex at Birth NORTHERN Health Authority (HA)

| Health Service Delivery Area | Age Group | # Enrolled | # on ART | # First Starts | # CD4 Tested | Median CD4 | # pVL Tested | Median pVL |
|------------------------------|--------------------|------------|------------|----------------|--------------|------------|--------------|---------------|
| NORTH EAST | 0 - 29 | 5 | * | 0 | * | * | * | * |
| | 30 - 49 | 20 | * | 0 | * | * | * | * |
| | 50 - 64 | 17 | * | 0 | * | * | * | * |
| | 65+ | 5 | * | 0 | * | * | * | * |
| | Total HSDA: | 47 | 38 | 0 | 42 | 595 | 34 | <40 |
| NORTH WEST | 0 - 29 | 0 | 0 | 0 | 0 | N/A | 0 | N/A |
| | 30 - 49 | 23 | 17 | 0 | 18 | 665 | 15 | <40 |
| | 50 - 64 | 35 | 32 | 0 | 32 | 550 | 25 | <40 |
| | 65+ | 11 | 10 | 0 | 10 | 520 | 8 | <40 |
| | Total HSDA: | 69 | 59 | 0 | 60 | 565 | 48 | <40 |
| NORTHERN INTERIOR | 0 - 29 | 8 | 6 | 0 | 8 | 760 | 6 | <40 |
| | 30 - 49 | 70 | 58 | 0 | 64 | 620 | 48 | <40 |
| | 50 - 64 | 70 | 60 | 0 | 68 | 495 | 51 | <40 |
| | 65+ | 30 | 29 | 0 | 30 | 550 | 27 | <40 |
| | Total HSDA: | 178 | 153 | 0 | 170 | 570 | 132 | <40 |
| Total HA: | | 294 | 250 | 0 | 272 | 570 | 214 | <40 |

| | Age Group | # Enrolled | # on ART | # First Starts | # CD4 Tested | Median CD4 | # pVL Tested | Median pVL |
|------------------|-----------|------------|------------|----------------|--------------|------------|--------------|---------------|
| | 0 - 29 | 13 | 10 | 0 | 12 | 760 | 9 | <40 |
| | 30 - 49 | 113 | 89 | 0 | 99 | 630 | 77 | <40 |
| | 50 - 64 | 122 | 107 | 0 | 116 | 545 | 89 | <40 |
| | 65+ | 46 | 44 | 0 | 45 | 490 | 39 | <40 |
| Total HA: | | 294 | 250 | 0 | 272 | 570 | 214 | <40 |

| Sex at Birth | # Enrolled | # on ART | # First Starts | # CD4 Tested | Median CD4 | # pVL Tested | Median pVL |
|--------------|------------|----------|----------------|--------------|------------|--------------|------------|
| Male | 193 | 171 | 0 | 182 | 605 | 147 | <40 |
| Female | 101 | 79 | 0 | 90 | 505 | 67 | <40 |
| Unknown | 0 | 0 | 0 | 0 | N/A | 0 | N/A |

| Currently on antiretroviral treatment | # of Participants | Median Age | Median CD4 | Median pVL |
|---------------------------------------|-------------------|------------|------------|---------------|
| Total HA: | 250 | 54 | 590 | <40 |

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Enrolled: Participants who had enrolled in the HIV Treatment Program, but not known to be deceased or formally reported as moved out of program
 # **on ART**: # of participants on antiretroviral treatment (ART) in the specified month based on dispensing record
 # **CD4** or **pVL** tested: participants tested for CD4 or pVL within the past 12 months and 6 months, respectively (CD4 in cells/ μ L and pVL in copies/mL)



4.14 Distribution of Participants by Program Duration NORTHERN Health Authority

| HSDA | Program Duration | # Enrolled | # on ART | # First Starts | # CD4 Tested | Median CD4 | # pVL Tested | Median pVL |
|-------------------|--------------------|------------|------------|----------------|--------------|------------|--------------|---------------|
| NORTH EAST | 10 years or more | 23 | * | 0 | * | * | * | * |
| | 5 years or more | 5 | * | 0 | * | * | * | * |
| | <5 years | 19 | * | 0 | * | * | * | * |
| | Never on ART | 0 | * | 0 | * | * | * | * |
| | Total HSDA: | 47 | 38 | 0 | 42 | 595 | 34 | <40 |
| NORTH WEST | 10 years or more | 48 | 42 | 0 | 42 | 545 | 34 | <40 |
| | 5 years or more | 9 | 7 | 0 | 7 | 820 | 5 | <40 |
| | <5 years | 12 | 10 | 0 | 11 | 620 | 9 | <40 |
| | Never on ART | 0 | 0 | 0 | 0 | N/A | 0 | N/A |
| | Total HSDA: | 69 | 59 | 0 | 60 | 565 | 48 | <40 |
| NORTHERN INTERIOR | 10 years or more | 112 | 99 | 0 | 108 | 550 | 81 | <40 |
| | 5 years or more | 37 | 29 | 0 | 34 | 615 | 30 | <40 |
| | <5 years | 29 | 25 | 0 | 28 | 585 | 21 | <40 |
| | Never on ART | 0 | 0 | 0 | 0 | N/A | 0 | N/A |
| | Total HSDA: | 178 | 153 | 0 | 170 | 570 | 132 | <40 |
| Total HA: | | 294 | 250 | 0 | 272 | 570 | 214 | <40 |

| | Program Duration | # Enrolled | # on ART | # First Starts | # CD4 Tested | Median CD4 | # pVL Tested | Median pVL |
|------------------|------------------|------------|------------|----------------|--------------|------------|--------------|---------------|
| | 10 years or more | 183 | 157 | 0 | 170 | 550 | 132 | <40 |
| | 5 years or more | 51 | 39 | 0 | 45 | 620 | 39 | <40 |
| | <5 years | 60 | 54 | 0 | 57 | 590 | 43 | <40 |
| | Never on ART | 0 | 0 | 0 | 0 | N/A | 0 | N/A |
| Total HA: | | 294 | 250 | 0 | 272 | 570 | 214 | <40 |

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Enrolled: Participants who had enrolled in HIV Treatment Program, not known to be deceased or formally reported as moved out of program

on ART: Participants on antiretroviral treatment (ART) in the specified month based on dispensing record (as above footnote)

Program Duration: years since first antiretroviral treatment dispensing in BC HIV Treatment Program

CD4 or pVL tested: participants tested for CD4 or pVL within the past 12 months and 6 months, respectively





4.15 Distribution of Antiretroviral Treatment Prescribers NORTHERN Health Authority

| HSDA of Prescriber Residency | # of Prescribers currently prescribing Antiretroviral Treatment | # of Participants currently treated by Prescribers | # of Prescribers ever prescribed Antiretroviral Treatment | # of Participants ever treated by Prescribers |
|------------------------------|---|--|---|---|
| NORTH EAST | 2 | * | 37 | 50 |
| NORTH WEST | 14 | * | 91 | 174 |
| NORTHERN INTERIOR | 22 | * | 129 | 551 |
| Total: | 38 | 228 | 257 | 775 |

| HSDA of Participant Residency | # of Participants with Prescriber out of HA/HSDA |
|-------------------------------|--|
| NORTH EAST | 8 |
| NORTH WEST | 25 |
| NORTHERN INTERIOR | 23 |
| Total: | 56 |

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Currently prescribing Antiretroviral Treatment: number of prescribers of antiretroviral treatment dispensed in the previous 6 months (based on participant HA/HSDA)

Currently treated: number of participants with antiretroviral treatment dispensed in the previous 6 months by antiretroviral treatment prescribers (based on follow-up prescriber HA/HSDA)

Prescribers ever prescribed Antiretroviral Treatment: for participants residing in HA/HSDA

Participants ever treated by prescribers: where follow-up prescriber is in the HA/HSDA

Participants with Prescriber out of HA/HSDA: participants residing in specified HA/HSDA with follow-up prescriber(s) in another HA/HSDA



4.16 Distribution of Indigenous Participants by Health Service Delivery Area and Sex at Birth

| HA | HSDA | # Enrolled | # on ART | # First Starts | # CD4 Tested | Median CD4 | # pVL Tested | Median pVL |
|-------------------|-----------------------------|------------|------------|----------------|--------------|------------|--------------|---------------|
| INTERIOR | EAST KOOTENAY | 5 | * | 0 | * | * | 5 | <40 |
| | KOOTENAY BOUNDARY | 6 | * | 0 | * | * | 5 | <40 |
| | OKANAGAN | 18 | * | 0 | * | * | 15 | <40 |
| | THOMPSON/CARIBOO/SHUSWAP | 21 | * | 0 | * | * | 15 | <40 |
| | Total HA: | 50 | 43 | 0 | 45 | 510 | 40 | <40 |
| FRASER | FRASER EAST | 32 | 25 | 0 | 26 | 640 | 27 | <40 |
| | FRASER NORTH | 44 | 39 | 0 | 35 | 450 | 38 | <40 |
| | FRASER SOUTH | 64 | 56 | 0 | 46 | 605 | 48 | <40 |
| | Total HA: | 140 | 120 | 0 | 107 | 540 | 113 | <40 |
| VANCOUVER COASTAL | NORTH SHORE/COAST GARIBALDI | * | * | 0 | * | * | * | * |
| | RICHMOND | * | * | 0 | * | * | * | * |
| | VANCOUVER | * | * | 0 | * | * | * | * |
| | Total HA: | 401 | 376 | 0 | 376 | 500 | 342 | <40 |
| VANCOUVER ISLAND | CENTRAL VANCOUVER ISLAND | 44 | 40 | 0 | 26 | 515 | 31 | <40 |
| | NORTH VANCOUVER ISLAND | 16 | 14 | 0 | 12 | 510 | 10 | <40 |
| | SOUTH VANCOUVER ISLAND | 44 | 39 | 0 | 15 | 550 | 31 | <40 |
| | Total HA: | 104 | 93 | 0 | 53 | 520 | 72 | <40 |
| NORTHERN | NORTH EAST | 12 | 9 | 0 | 11 | 480 | 8 | <40 |
| | NORTH WEST | 33 | 26 | 0 | 28 | 515 | 23 | <40 |
| | NORTHERN INTERIOR | 65 | 54 | 0 | 64 | 560 | 47 | <40 |
| | Total HA: | 110 | 89 | 0 | 103 | 540 | 78 | <40 |
| Total: | | 805 | 721 | 0 | 684 | 510 | 645 | <40 |

| Sex at Birth | # Enrolled | # on Antiretroviral Treatment | # First Starts | # CD4 Tested | Median CD4 | # pVL Tested | Median pVL |
|--------------|------------|-------------------------------|----------------|--------------|------------|--------------|------------|
| Male | 505 | 459 | 0 | 426 | 510 | 409 | <40 |
| Female | 300 | 262 | 0 | 258 | 515 | 236 | <40 |
| Unknown | 0 | 0 | 0 | 0 | N/A | 0 | N/A |

| Currently on antiretroviral treatment | # of Participants | Median Age | Median CD4 | Median pVL |
|---------------------------------------|-------------------|------------|------------|---------------|
| Total: | 721 | 55 | 530 | <40 |

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Enrolled: Participants who had enrolled in the HIV Treatment Program, but not known to be deceased or formally reported as moved out of program

on Antiretroviral Treatment: defined as # of Participants being on antiretroviral treatment in the specified month

CD4 or pVL tested: participants tested for CD4 or pVL within the past 12 months and 6 months, respectively (CD4 in cells/μL and pVL in copies/mL)





BRITISH COLUMBIA
CENTRE *for* EXCELLENCE
in HIV/AIDS

Funding for the BC Centre for Excellence in HIV/AIDS and HIV Drug Treatment Program provided in-part by:

